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NMDARs are ligand-gated cation channels which are activated by the neurotransmitter
glutamate.  NMDARs  are  essential  in  coupling  electrical  activity  to  biochemical
signalling as a consequence of their high Ca2+ permeability. This Ca2+ influx acts as a
secondary messenger to mediate neurodevelopment, synaptic plasticity, neuroprotection
and neurodegeneration.  The biological outcome of NMDAR activation is determined by
a  complicated  interrelationship  between  the  concentration  of  Ca2+ influx,  NMDAR
location (synaptic vs. extrasynaptic) as well as the subtype of the GluN2 subunit. Despite
the recognition that NMDAR mediated physiology is multifaceted, tools used to study
subunit and location dependent signalling are poorly characterized and in other cases,
non-existent. Therefore, the aim of this thesis is to address this issue. 
      
Firstly,  I  assessed  the  current  pharmacological  approach  used  to  selectively  activate
extrasynaptic NMDARs. Here, synaptic NMDARs are first blocked with MK-801 during
phasic  activation  and  then  extrasynaptic  NMDARs  are  tonically  activated.   This
approach relies on the continual irreversible blockade of synaptic NMDARs by MK-801
yet contrary to the current dogma, I demonstrate this blockade is unstable during tonic
agonist  exposure  and even more  so  when physiologically  relevant  concentrations  of
Mg2+ are  present.  This  confines  a  temporal  limit  in  which  selective  activation  of
extrasynaptic NMDARs can occur with significant consequences for studying synaptic
vs. extrasynaptic NMDAR signalling.
    
Dissecting subunit-dependent signalling mediated by the two major GluN2 subunits in
the  forebrain,  GluN2A and  GluN2B,  has  been  advanced  significantly  by  selective
GluN2B antagonism yet  a  reciprocal  GluN2A selective  antagonist  has  been lacking.
Utilizing  novel  GluN2A-specific  antagonists,  I  demonstrate  a  developmental
upregulation  of  GluN2A-mediated  NMDA currents  which  concurrently  dilutes  the
contribution of GluN2B-mediated currents. Moreover, I tested the hypothesis that the C-
terminus of GluN2A and GluN2B are essential in controlling the developmental switch
of  GluN2  subunits  utilizing  knock-in  mice  whereby  the  C-terminus  of  GluN2A is
replaced with that of GluN2B. Surprisingly, the exchange of the C-terminus does not
impede the developmental switch in subunits nor the proportion of NMDARs at synaptic
vs  extrasynaptic  sites.  However,  replacing  the  C-terminus  of  GluN2A with  that  of
GluN2B induces a greater neuronal vulnerability to NMDA-dependent excitotoxicity. 
     
Collectively, this work enhances our understanding of the complex physiology mediated
by the NMDAR by determining how pharmacological tools are best utilized to study the
roles  of  NMDAR  location  and  subunit  composition  in  addition  to  revealing  the
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Glutamate  is  the  major  excitatory  neurotransmitter  in  the  mammalian  central
nervous system (CNS). At the postsynaptic membrane, glutamate can activate a host
of receptors as summarized in Figure 1.1. 
  
Figure 1.1  : Summary of receptors activated by the neurotransmitter glutamate. The
receptors can largely be split into groups where one class conducts ions on activation
of glutamate (ionotropic) and the other relays chemical messengers (metabotropic). 
GluA2-containing AMPA receptors and kainate receptors are highly permeable to
Na+  and are thus suited to generating fast excitatory transmission in accordance
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receptors  (NMDARs),  AMPA receptors  lacking  the  GluA2 subunit,  and  group  I
metabotropic receptors  all  cause an increase in  post-synaptic Ca2+ levels.  This is
noteworthy as Ca2+  can act as a secondary messenger in order regulate a wide array
of  brain  functions;  the  divalency,  ionic  radius  and  complex  electron  shell
configuration of Ca2+ makes it suited to induce conformational changes in proteins
(Bading 2013). 
Ca2+  signalling by NMDARs is now well established to be involved in important
physiological functions such as learning and memory in addition to pathological
conditions such as stroke and neurodegenerative diseases  (Giles E Hardingham &
Bading 2010). Furthermore, in recent years, it has become ever more apparent that
the  dysregulation  of  NMDARs  is  involved  in  a  number  of  epileptic  and
neuropsychiatric disorders (Lakhan et al. 2013). 
The aim of this thesis is to aid in elucidating the complex signalling by NMDARs
with  particular  focus  on  spatial  and subunit-specific  signalling  by the  NMDAR.
Therefore,  this  introduction  will  cover  the  following  regarding  the  NMDAR:
structure and how it relates to its function; temporal and spatial patterns of subunit
expression during development; pharmacology; neuroprotective and neuronal death
signalling; learning & memory, and finally, its role in diseases. 
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1.1 The Relevance of NMDAR Structure in Relation to its Function
1.1.1 NMDA subunit structure
In  the  forebrain,  most  NMDARs  are  tetrameric  ion  channels  consisting  of  two
GluN1  subunits  and  two  GluN2  subunits.  The  arrangement  of  the  subunits  has
previously been contentious; evidence existed for an adjacent/“1/1/2/2” (Balasuriya
et  al.  2013)  or  alternating/“1/2/1/2”  (Riou  et  al.  2012)  subunit  configuration.
However,  the recent determination of the X-ray crystal structure of the NMDAR
unequivocally confirms the subunit arrangement is alternate (Lee et al. 2014).  The
structure of the NMDAR subunit is illustrated in  Figure 1.2; a brief summary of
each component shall be given below and elaborated on in further sections where
necessary. 
Figure 1.2: Structure of the NMDAR subunit. Image from (Wyllie et al. 2013)
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The amino-terminal domain (ATD) largely provides sites for allosteric modulation.
For example, Zn2+ and H+ are endogenous allosteric modulators which bind to the
GluN2 ATD  (Karakas  et  al.  2011;  Furukawa 2012).  The ligand binding  domain
provides an agonist site for glycine or D-serine to bind to GluN1 or glutamate to
bind  to  GluN2.  The  transmembrane  domain  and  adjacent  amino  acids  largely
determine the biophysical properties of the NMDAR.  Lastly,  the primary function
of the CTD is to couple Ca2+ to intracellular signalling and regulate trafficking of the
NMDAR via post-translational modifications cascades in addition to being essential
for correct gating of the NMDAR. 
The  GluN1 and  GluN2 subunits  can  be  modulated  by a  variety  of  endogenous
molecules and ions as illustrated in Figure 1.3.A.   This complex regulation in part
explains the physiology of the NMDAR which shall now be elaborated on below. 
1.1.2 The NMDA receptor as a co-incidence detector
The NMDAR is a ligand-gated ion channel as it requires the binding of glycine/D-
serine  to  the  GluN1  subunit  and  glutamate  binding  to  the  GluN2  subunit;
occupation of all four binding sites induces a conformational change in the receptor.
However, at resting membrane potentials (-60 mV to -70 mV), there is very little ion
flow in the open state of the channel as the channel pore is  blocked by Mg2+. Post-
synaptic  depolarization,  largely  through  the  activation  of  AMPA  and  kainate
receptors, can alleviate this Mg2+  block.  Therefore, to permit ion flow, the NMDAR
requires  synchronization  of  pre-synaptic  release  of  glutamate  and  post-synaptic
depolarization hence why it  is  known as a co-incidence detector (Figure 1.3.B).
Although Ca2+/Na+ influx intracellularly is the most studied ion conductance of the
NMDAR, there is also a K+   efflux.  This K+   efflux can enhance  presynaptic Ca2+
transients  and  neurotransmitter  release,  induced  by  local  depolarization  at  the
synaptic cleft, which is a candidate mechanism for promoting spike time dependent
plasticity (Shih et al. 2013). 
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Figure 1.3: A) Illustration of agonist and modulatory sites on the GluN1 and GluN2
subunits.  B) Schematic  showing  how  the  NMDAR  operates  as  a  co-incidence
detector. Presynaptic release of glutamate is required so glutamate can bind to the
GluN2  subunit  and  if  glycine/D-serine  is  also  bound  to  the  GluN1  subunit,  a
conformational  change  results  in  the  NMDAR  channel  opening.  However,
intracellular depolarization is also required to alleviate the Mg2+ block of the channel
pore. Therefore, to permit the flow of cations, the NMDAR requires presynaptic




It should be noted that it  was recently reported that the NMDARs may have the
capacity to function independently of ion influx and act purely as a metabotropic
receptor  (Nabavi  et  al.  2013;  Kessels  et  al.  2013).  This  conclusion  was  partly
derived from the observation that competitive antagonists acting at the GluN1 and
GLuN2  agonist  sites  can  block  long-term  depression  (LTD)  but  open  channel
channel blocker failed to do so.  However, this hypothesis has since been refuted by
reports that open channel blockers do indeed block LTD emphasizing the classical
role of Ca2+ influx in mediating synaptic plasticity(Babiec et al. 2014). 
1.1.3 GluN1 subunit
Both GluN1 subunits of the tetramer must be bound by either glycine or D-serine in
order  for  the  NMDAR channel  to  open.  The  purpose  of  this  obligatory agonist
binding  site  is  not  well  understood.  Levels  of  glycine  and  D-serine  in  the
extracellular fluid of the cortex are high enough to saturate NMDARs (Matsui et al.
1995) leading some to suggest the agonist site may be saturated in vivo. However,
this fails to take into account the release, uptake and metabolism of these amino
acids. For example, by co-expressing the glycine transporter (GLYT1) with NMDA
receptors in oocytes, it was observed glycine concentrations could decrease from a
saturating concentration to < EC50  in a matter of seconds  (Supplisson & Bergman
1997).  Furthermore,  GlyT1+/- have  enhanced  NMDAR:AMPAR ratio  in  CA1 in
pyramidal  neurons  suggesting  glycine  uptake  is  critical  for  regulating  synaptic
NMDAR activation (Tsai et al. 2004; Gabernet et al. 2005). 
Recently,  using  enzymes  which  degrade  either  D-serine  or  glycine,  it  has  been
proposed  that  D-serine  activates  synaptic  NMDARs  whereas  glycine  activates
extrasynaptic  NMDARs  (Papouin et  al.  2012).   However,  while  serine racemase
knock-out  (SR-KO)  mice  have  clear  deficits  in  LTP  due  to  their  inability  to
synthesise  serine,  NMDAR  synaptic  potentials  are  preserved  in  these  mice
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suggesting  some overlap  of  glycine  and  serine  at  the  synapse  (Rosenberg  et  al.
2013). 
The GluN1 subunit has 3 regions of alternative splicing, one at the N-terminus and
two at the C-terminus,  which can result in 8 different isoforms. The isoforms can
result in different trafficking mechanisms (Horak & Wenthold 2009) and functional
differences  such  as  altering  NMDA  receptor  dependent  regulation  of  gene
expression  (Bradley et  al.  2006). The alternative splicing is  developmentally and
regionally  regulated  but  despite  this,  the  GluN1-1a  subtype  is  the  most  widely
expressed in the CNS and is the canonical subtype (Cull-Candy et al. 2001). 
1.1.4 GluN2 subunit
1.1.4.1  GluN2 subunit:  amino terminal  domain,  ligand binding domain and
transmembrane domain 
There  are  4  genes,  Grin2a-d,   which  encode  for  four  GluN2  subunits  (A-D).
Incorporation of different subunits alters the biophysical properties of the channels
as summarized in Table 1.1.
When  considering  NMDAR  sensitivity  to  Mg2+,  Ca2+ permeability  and  single-
channel  conductance,  NMDARs  containing  GluN2A/GluN2B  subunits  are
biophysically  similar  as  are  GluN2C/GluN2D.  This  can  largely  be  attributed  to
2A/2B having a serine residue (Ser632 in GluN2A) at the intracellular side of the
third membrane-associated domain whereas 2C/2D have a leucine residue (Leu657
in  GluN2D)  (Siegler  Retchless  et  al.  2012).  This  single  amino  acid  difference
dramatically  alters  the  Mg2+ block,  Ca2+ permeability  and  single  channel
conductance of the NMDAR.
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GluN2A GluN2B GluN2C GluN2D
GluN1 agonist
potency
↑ ↑↑ ↑↑↑ ↑↑↑↑
GluN2 agonist
potency
↑ ↑↑ ↑↑↑ ↑↑↑↑↑
Deactivation
rate





























Conductance 50/40 pS 35/18 pS
Table  1.1: Incorporation  of  different  GluN2  subunits  alters  the  biophysical
properties  of  NMDARs.  Adapted  from  (Wyllie  et  al.  2013)with  additional
information from (Zhang et al. 1994; Rachline et al. 2005)
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1.1.4.2 GluN2 Subunit: the CTD of GluN2A and GluN2B
The extracellular and transmembrane domains are highly conserved (69%) between
GluN2A and GluN2B. However, when considering the C-terminal domain region, it
is poorly conserved with only 29% homology (Ryan et al. 2008). Although deletion
of GluN2A and GluN2B CTDs can alter channel conductance and gating, switching
the CTDs between GluN2A and GluN2B does not alter the properties of the chimera
channels  (Maki et al. 2012; Punnakkal et al. 2012). It can therefore be concluded
that the divergence of the CTD between GluN2A and GluN2B does not contribute to
subunit-specific gating properties but is an essential structural component in order
for the NMDAR to function correctly. On the other hand, there is an abundance of
evidence which supports the hypothesis that the divergence of the CTDs allows the
different  subunits  to  couple  to  different  intracellular  signalling  cascades;  a  brief
summary of these is given in  Table 2 with many being elaborated in subsequent
sections where necessary.  
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SAP-102  & 
PSD-95
(Elias et al. 2008)
SAP-102 can traffick both GluN2B &
GluN2A whereas  PSD-95 can only
traffick GluN2A. Both stabilize
NMDARs at the synapse. As they both
have structurally similar PDZ domains,
they both can have the potential to
couple NMDARs to similar proteins.
However, they undergo different post
translational modification ; e.g only






(Yang et al. 2012)
Phosphorylation of Tyr1472 at GluN2B
prevents clathrin adaptor protein AP-2
binding to YEKL motif: ultimately
reduces endocytosis
STEP
(Braithwaite et al. 2006)






(Cerne et al. 1993)
PSD-95 associates with A kinase
anchoring proteins allowing PKA to
increase NMDA currents. 
PKC
(Gardoni et al. 2001)
(Liao et al. 2001)
Phosphorylation  of GluN2A (ser-
1416) and GluN2B (ser1303/1323)




Phosphorylation of ser1480 disrupts
interaction of GLuN2B with PSD-
95/SAP-102
DAPK
(Tu et al. 2010)
CaMKII
(Liao et al. 2001)
Phosphorylates ser1303 of GluN2B
CTD and enhances NMDA currents
PP1  and calcineurin 
(Wang et al. 1994)
Antagonizes the actions of PKA and
PKC. 
Palmitoylation -
(Hayashi et al. 2009)
Can enhance NMDA stability at
membrane by enhancing Fyn
phosphorylation. At other sites, leads to
increase accumulation in golgi
apparatus and decreased surface
expression. 
Table 1.2: A summary of post-translational modifications of  GluN2A and GluN2B
CTDs. 
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1.1.6 The GluN3 subunit
The physiological role of the GluN3 subunit is less well known than the GluN2
subunit. Diheteromeric GluN1-GluN3 NMDARs are gated exclusively by glycine,
have no Mg2+ block and are only permeable to Na+ and K+. However, they may be
incorporated  into  a  triheteromeric  NMDAR  with  another  GluN2  subunit.  This
dramatically alters the property of the NMDAR by acting as a  dominant-negative
modulator of the GluN2 subunit;  a reduction in Mg2+ block and Ca2+ influx is  a
defining  feature  (Pachernegg  et  al.  2012).  In  layer  2/3  visual  cortical  neurons,
GluN3A forms a triheteromeric NMDAR with GluN2B presynaptically ; the reduced
Mg2+ block enhances spontaneous and evoked glutamate release which is critical for
spike timing-dependent LTD  (Larsen et al. 2011). Interestingly, in forebrain regions,
GluN3A declines  during development  as  GluN2A increases  so it  is  feasible  that
GluN3A limits  synaptic  development.  Indeed,  knockout  of  GluN3A accelerates
synaptic maturation (Henson et al. 2012) whereas overexpression  delays maturation
(Roberts  et  al.  2009).  Whether  spike  timing-dependent  LTD  synchronizes  this
developmental break remains an interesting and open question.  
1.1.7 Triheteromeric (GluN2A-GluN2B) NMDARs 
Much  of  the  research  regarding  GluN2  containing  NMDARs  has  assumed  the
tetramer  is  composed  of  GluN2 subunits  of  the  same subtype.  However,  recent
evidence suggests this may not be the case. For example, at hippocampal synapses
in culture (Tovar et al. 2013) and in vitro slices (Gray et al. 2011; Rauner & Köhr
2011), it has been reported that there is a prominent population of triheteromeric
NMDARs containing GluN1, GluN2A and GluN2B subunits.  Their existence may
explain the recent rejection of a well researched hypothesis that one diheteromeric
GluN2  population  may  induce  LTP  and  another  population  may  induce  LTD
(Shipton & Paulsen 2014). This shall be elaborated on in further sections. 
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Due to the difficulty of isolating triheteromeric NMDARs,  little is known about
their structure and how it relates to their function at the molecular level. However,
an elegant approach to rectify this has recently been established by (Hansen et al.
2014). When assessing glutamate deactivation time course after a 5 ms glutamate
pulse, triheteromeric GluN2A-GluN2B NMDARs are 1.8-fold slower than that of
GluN1/GluN2A  diheteromers  but  5.5-fold  faster  than  that  of  GluN1/GluN2B
diheteromers;  this  suggests  GluN2A  largely  determines  the  decay  kinetics  of
triheteromeric  GluN2A-GluN2B  NMDARs.  Additionally,  GluN2A-GluN2B
NMDARs have a distinct pharmacological profiles which shall be discussed below. 
As discussed above, the CTD of GluN2A and GluN2B have diverged significantly.
If the assumption is made that during Ca2+ influx, both CTDs of the two  GluN2
subunits are exposed to the same Ca2+ concentrations in a triheteromeric NMDAR, it
is feasible that functions such as synaptic plasticity could be determined by the Ca2+
affinity of the proteins coupled to the CTDs. 
It  is  clear  that  further  research  into  the  structure  of  triheteromeric  NMDARs is
critical in order to fully understand the complex physiology of NMDARs. 
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1.2 Temporal and spatial patterns of NMDAR subunit expression
during development
As  discussed  above,  incorporation  of  different  GluN2  and  GluN3  subunits  can
dramatically alter the properties of NMDARs. As shown in Figure 1.4, GluN2 and
GluN3 subunits change their temporal and spatial patterns during development in
the rodent brain. They also show distinct spatial expression patterns depending on
the brain region. For example , GluN2C and GluN2D are expressed strongly in the
hindbrain during development and adulthood whereas in the forebrain,  GluN2A and
GluN2B are more strongly expressed.  
Figure 1.4: temporal  and spatial  patterns  of NMDAR subunit  expression during
development. Note the developmental upregulation of GluN2A in the hippocampus
and cortex. Adapted from (Paoletti et al. 2013)
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From this point on, this thesis will focus on the forebrain region. The reason being
that  this  brain  region  can  undergo  widespread  excitotoxicity  during  a  stroke  or
traumatic brain injury in addition to being a critical location for neurodegenerative
diseases such as A1zheimer's disease. Secondly, the hippocampus is the most widely
studied structure regarding synaptic plasticity which is currently the best candidate
molecular mechanism underlying learning and memory. Lastly, the data presented in
this thesis was derived using cortical cultures as a model to study subunit-dependent
and spatial signalling by the NMDAR; cortical and hippocampal cultures have been
used extensively for this purpose  (Hardingham & Bading 2010). 
1.2.1 Temporal expression of GluN2 subunits in hippocampus and cortex
At early stages in development, both in the cortex and the hippocampus, GluN2B is
the  dominant  GluN2  subunit  expressed.  However,  during  development  there  is
upregulation of GluN2A. This has been noted at the mRNA level  (Watanabe et al.
1992;  Monyer  et  al.  1994),  at  the  protein  level  in  synaptosomal  preparations
(Portera-Cailliau et al. 1996) and by co-immunoprecipitation with GluN1 (Sheng et
al. 1994). By injecting oocytes with mRNA prepared from P1 and adult whole rat
brains, (Williams et al. 1993) could detect a decrease in the sensitivity of NMDARs
to the GluN2B selective antagonist  ifenprodil.  This  drop in GluN2B antagonism
could be recapitulated in developing rat cortical cultures (Tovar & Westbrook 1999;
Ilyin et al. 1996; M-A Martel et al. 2009), developing mouse hippocampal cultures
(Thomas et al. 2006) or in acutely dissociated parietal cortical neurons from young
and  old  rats  (Kew  et  al.  1998).  In  hippocampal  and  cortical  slices,  there  is  a
developmental increase in the speed of NMDA EPSC decay kinetics (Carmigoto &
Vicini 1992) indicating an increase in GluN2A at the synapse and this correlates
very well with a drop in the sensitivity of EPSCs to GluN2B antagonism (Kirson &
Yaari 1996).  Furthermore,  elegant studies implementing single-cell  RT-PCR have
correlated  an  increase  in  GluN2A mRNA with  a  drop  in  ifenprodil  sensitivity
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(Hoffmann et al. 2002) and an increase in EPSC decay kinetics (Flint et al. 1997) at
the single cell level. Altogether, the change in biophysical properties and drop in
ifenprodil  sensitivity of  the NMDAR EPSC in  a  variety of  preparations  suggest
GluN2A  containing  NMDARs  are  incorporated  into  the  synapse  during
development.  This  is  commonly  known  as  the  “GluN2B  to  GluN2A “switch”.
However, as discussed, there is now evidence for a strong triheteromeirc GluN2A-
GluN2Bs so the upregulation of GluN2A may not be as binary as once thought ; it is
perhaps best to hypothesise the GluN2A  upregulation as an incorporation. 
Studies implementing immunoprecipation agree that the upregulation of GluN2A is
incorporated into diheteromeric and triheteromeric GluN2A-GluN2B NMDARs but
the ratio at which this occurs is not clear (Al-Hallaq et al. 2007; Sheng et al. 1994;
Luo et  al.  1997).  However,  as  stated above,  at  hippocampal  synapses  in  culture
(Tovar et al. 2013) and in vitro slices (Gray et al. 2011; Rauner & Köhr 2011), it has
been  reported  that  there  is  a  prominent  population  of  triheteromeric  GluN2A-
GluN2B NMDARs at  the  synapse.  Furthermore,  overexpression  of  GluN2A has
been noted to decrease lateral diffusion of GluN2B containing NMDARs suggesting
GluN2A forms  a  triheteromer  with  GluN2B thus  stabilizing  the  receptor  at  the
synapse (Groc et al. 2006). 
1.2.2 Molecular mechanisms underlying GluN2A upregulation
The  developmental  increase  in  Grin2a mRNA described  above  is  an  excellent
candidate  mechanism  to  explain  the  developmental  upregulation  of  GluN2A
containing NMDARs. However, transcriptional control of GluN2 subunit expression
could also occur by a downregulation of  Grin2b. Indeed,  the repressor element 1
silencing transcription factor (REST) is essential for epigenetically reducing Grin2b
transcription  and  if  REST  is  genetically  knocked-out,  there  is  a  deficit  in  the
developmental switch in subunits (Rodenas-Ruano et al. 2012). Such a phenomenon
would  not  explain  the  rapid  switching  in  GluN2 subunits  in  minutes,  discussed
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below,  due to the time scale of epigenetic modelling. 
A striking observation is that in neuronal cultures, where the network activity is
artificially created and is somewhat oscillatory in nature, the developmental switch
in GluN2 subunits still occurs. This suggests that a specific electrical input is not
necessary for this developmental process to occur.  However,  in young hippocampal
slices  predominately  expressing  GluN2B,  there  can  be  a  rapid  upregulation  of
GluN2A at the synapse within minutes by a LTP induction protocol which is also
reversible (Bellone & Nicoll 2007). Although it is debatable whether such protocols
are physiologically relevant, it is of great interest that that subunits can switch in
such a  time  scale.  Such protocols  have  been used  as  an  assay to  determine  the
molecular  mechanisms  involved  in  the  upregulation  of  GluN2A;  mGluR5  and
NMDAR activation  were  found to  be essential  (Matta  et  al.  2011).  In  the  CA1
region  of  the  hippocampus,  in  mGluR5 knock-out  mice,  there  is  an  incomplete
reduction  in  the  developmental  switch  of  NMDA subunits  suggesting  there  are
overlapping  signalling  cascades  involved  in  the  switch  with  mGluR5  signalling
being prominent. 
A variety of post-translational modifications have been proposed to be involved in
the  developmental  switch  in  subunits.  Casein  kinase  II  (CK2)  phosphorylates
ser1480  of  the  GluN2B which  drives  endocytosis;  this  kinase  activity  increases
during the time window of the developmental switch and is critical in the increase of
GluN2A at  the  synapse  (Sanz-Clemente  et  al.  2010).  The  molecular  mechanism
underlying the enhanced endocytosis involves phosphorylation of S1480 disrupting
the interaction PSD-95/SAP102 with  the PDZ domain of the GluN2B CTD (Chung
et al. 2004). This has the consequence of Y1472 being able to be dephosphorylated
and  AP-2  binding  to  the  YEKL  motif  thus  promoting  GluN2B  endocytosis.
Furthermore, the N-terminal of SAP-102 binds to a non PDZ binding site on the
GluN2B  CTD  where  it  promotes  lateral  diffusion  of  NMDARs  to  perisynaptic
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endocytic zones  (Chen et al. 2012). 
Additionally,  CK2  can  be  regulated  by  Ca2+ influx  through  the  NMDAR albeit
indirectly via CaMKII. Ca2+/calmodulin-dependent protein kinase II (CaMKII) binds
to  the  Glu2NB CTD in  the  region 1290-1309  (Strack  et  al.  2000) where  it  can
promote the phosphorylation of ser1480 by CK2 (Chung et al. 2004). However, CK2
is  a  constitutively  active  kinase  (Olsten  &  Litchfield  2004) so  CaMKII  cannot
regulate  CK2 via its  kinase activity;  it  has  been proposed that  CaMKII forms a
trimolecular  complex with  CK2 and the  PDZ domain  of  the  GluN2B CTD and
promotes CK2 phosphorylation of ser1480 via physical interaction (Sanz-Clemente
et al. 2013). It should be noted that inhibiting synaptic activity, blocking NMDARs
or  blocking  CaMKII  does  not  block  basal  ser1480  phosphorylation  entirely  but
reduces it to around 50%. Furthermore, inhibition of CaMKII failed to prevent the
developmental switch in subunits induced by an LTP protocol (Matta et al. 2011). 
It is also interesting to note that dark rearing rats from birth can result in an increase
in the phosphorylation of the GluN2B CTD at ser1303 which correlates with a delay
in  the  upregulation  of  GluN2A  in  the  visual  cortex  and  retina;  even  more
remarkable,  only  6  hours  of  light  can  reverse  both  the  delayed  expression  of
GluN2A and the increased phosphorylation of ser1303 (Giannakopoulos et al. 2010).
Ser1303 is a target for PKC, DAPK and CaMKII; although these experiments do not
prove that CaMKII phosphorylation of Ser1303 delays the switch, it is intriguing to
note that dark rearing increases CaMKII expression in the retina (Xue et al. 2001). 
SAP-102 is expressed predominately in the neonatal brain with an increase of PSD-
95 expression occurring in the first several months post birth; SAP-102 somewhat
mirrors the temporal expression of GluN2B and PSD-95 mirrors that of GluN2A.
Whereas SAP-102 is critical in synaptogenesis where it can promote the trafficking
of both GluN2B and GluN2A NMDARs, PSD-95 is critical  after  synaptogenesis
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where it maintains the developmental switch of GluN2 subunits; the molecular basis
for this may be that PSD-95 only promotes the trafficking of GluN2A NMDARs
(Elias et al. 2008).   
Blockade  of  NMDARs  and  AMPARs  has  been  reported  to  increase  GluN2A
expression  within  hours  with  no  effect  on  GluN2B  expression  in  culture  (von
Engelhardt et al. 2009). As TTX could not reproduce this effect, it must be presumed
the effect is due to blocking miniature synaptic events which can tonically suppress
local dendritic protein synthesis (Sutton et al. 2006). Nevertheless, this phenomenon
has yet to be explored in any great detail.  
To summarize, there is evidence that the upregulation of GluN2A is controlled by
both transcriptional and post-translational mechanisms. One possible mechanism to
test  the  role  of  post-translational  mechanisms  is  to  subject  both  GluN2B  and
GluN2A to the same regulation; this can be achieved by genetically replacing the
GluN2A CTD with that of GluN2B. Such an approach is utilized in chapter 5 where
I determine if the developmental upregulation of GluN2A is impeded. 
1.2.3 The physiological outcome of GluN2A upregulation
During a synaptic event,  a diheteromeric GluN2B-NMDAR carries approximately
twice  the  charge  of  a  diheteromeric  GluN2A-NMDAR  (Erreger  et  al.  2005).
Furthermore, per unit of charge, GluN2B-NMDARs carry more Ca2+ that GluN2A-
NMDARs (Sobczyk, et al. 2005). Lastly, the GluN2B CTD has a higher affinity for
CAMKII than the GluN2A CTD; there is ever increasing evidence that CAMKII is
necessary for certain forms of synaptic plasticity (see   (Nicoll & Roche 2013 for a
review;  section 1.5 for a greater discussion on synaptic plasticity). Altogether, the
difference in Ca2+ permeability and CAMKII affinity results in GluN2B-NMDARs
having a lower threshold for the induction of long-term potentiation (LTP) compared
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to GluN2A-NMDARs. 
Consequently,  the  developmental  upregulation  of  GluN2A  will  increase  the
threshold for LTP induction. However, importantly, the GluN2A:GluN2B ratio is not
fixed and can be modified by neural activity; the modification of synaptic plasticity
itself is known as metaplasticity (see Abraham 2008 for a review).  For example,
monocular deprivation in mice leads to a decrease in the GluN2A:GluN2B ratio in
the visual cortex which juxtaposes in a lowering of LTP induction (Chen & Bear
2007, Philpot et al. 2007). Genetic deletion of GluN2A disrupts the modification of
the  LTP  threshold  during  monocular  deprivation  thus  confirming  the
GluN2A:GluN2B dictates the threshold for LTP (Cho et al. 2009). 
It has also been demonstrated that the divergence of the GluN2A and GluN2B CTD
has resulted in different forms of plasticity and behaviours (Ryan et al. 2013) which
would be absent if the upregulation of GluN2A failed to occur. In agreement, genetic
deletion of either the whole GluN2A subunit or the CTD alone resuls in impaired
spatial working memory (Bannermann et al. 2008)
The  upregulation  of  GluN2A has  also  been  noted  to  alter  synaptogenesis  (see
section 1.2.4.1) and excitotoxicity (see section 1.4.3 & chapter 5). 
1.2.4 Spatial expression of NMDARs at the neuronal level during development
1.2.4.1 Synaptogenesis
Although it is beyond the scope of this thesis to discuss the complex physiology
underlying synaptogenesis, nevertheless, a basic appreciation of this phenomenon is
required to appreciate NMDAR signalling during development. 
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During the first postnatal week, dendritic shafts are covered with filopodia which
protrude and retract with a life time of approximately 10 minutes where synapses
can form. However,  predominately during the second developmental  week,   if  a
filopodia  comes  into  contact  with  a  developing  axon,  a  complex  cross-stalk
signalling process can take place which can result in the development of a dendritic
spine  (Calabrese et  al.  2006).  This  complex signalling can involve cell-adhesion
proteins and chemically released transmitters. During this time period, NMDARs
largely switch from predominately existing outside the synapse or “extrasynaptic
NMDARs (exNMDARs)”  to  predominately  existing  at  the  synapse  or  “synaptic
NMDARs  (synNMDARs)”.  This  switch  in  NMDAR membrane  location  is  also
recapitulated  in  neuronal  cultures  (Tovar  & Westbrook 1999;  M-A Martel  et  al.
2009) where  spines  are  noted  to  increase  rapidly between  DIV 10 and DIV 14
(Boyer et al. 1998). 
NMDARs  have  been  proposed  to  control  synaptogenesis.  For  example,
overexpression of GluN2B increases spine motility whereas GluN2A overexpression
was noted to stop synapse number and growth in organotypic hippocampal slices
(Gambrill & Barria 2011). However, knocking down both AMPAR and NMDAR
mediated  synaptic  transmission  in  a  single  neuron  in  vivo failed  to  alter  spine
development  arguing  that  ionotropic  glutamatergic  synaptic  transmission  is  not
required for spine development   (Lu et al. 2013). This observation is consistent with
pharmacological  silencing  of  network  activity  in  culture  which  failed  to  alter
dendritic  spine  formation  or  density  (Harms & Craig 2005;  Kossel  et  al.  1997).
Additionally, a well defined genetic programme required for synapse assembly can
operate without network activity  (Valor et  al.  2007). However,  it  is important to
stress that tetrodotoxin is the most common pharmacological approach to silence
neuronal  activity;  this  approach still  permits  miniature  synaptic  events  to  occur.
Nevertheless, the observations from Lu et al are striking and would certainly warrant
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further investigations to determine if compensations from metabotropic glutamate
receptors had occurred. 
1.2.4.2 Surface mobility of NMDAR
By blocking synaptic NMDARs with MK-801, which has very slow off rate, it was
observed  that  the  recovery  of  this  blockade  could  only  be  explained  by  the
movement  of  NMDARs  from  outside  the  synapse  into  the  synapse  (Tovar  &
Westbrook 2002). Under high resolution imaging, it has been observed that GluN2B
containing  NMDARs  are  more  mobile  than  GluN2A,  with  GluN2A spending  a
greater time at the synapse; as stated above, overexpression of GluN2A decreases
the  mobility  of  GluN2B  possibly  because  of  the  formation  of  triheteromeric
GluN2A-GluN2B NMDARs (Groc et al. 2006). Interestingly, after endocytosis, the
GluN2B CTD is trafficked through recycling endosomes whereas the GluN2A is
sorted  into  late  endosomes  destined  for  degradation;  the  GluN2A CTD  can  be
“rescued” from degradation if  it  forms a  heterodimer with GluN2B  (Tang et  al.
2010).  Therefore,  it  is  interesting  to  speculate  that  in  a  triheteromeric  GluN2A-
GluN2B  NMDAR,  the  GluN2B  subunit  prolongs  the  half-life  of  the  receptor
whereas the GluN2A subunits promotes stability at the synapse. 
It has been reported that GluN2A containing NMDARs are preferentially targeted to
the synapse via a mechanism involving the CTD (Steigerwald et al. 2000) but this
finding  could  not  be  recapitulated  in  subsequent  studies  (Thomas  et  al.  2006).
Furthermore,  a  loss  of  ifenprodil  sensitivity is  observed at  extrasynaptic  sites  in
culture (M-A Martel et al. 2009) and hippocampal slices (Harris & Pettit 2007). The
latter study does not report the mobility of NMDARs previously reported by Tovar
& Westbrook with a possible explanation that NMDAR mobility is an artefact of the
culture system; further work is needed to determine if NMDARs form stable pools
or are mobile  in vivo.  Lastly, D-Serine has been proposed to slow the mobility of
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GluN2A containing NMDARs whereas glycine to slow the mobility of GluN2B in
cultures (Papouin et al. 2012). 
To summarize, it is evident that NMDARs switch from predominately extrasynaptic
to  synaptic  during  the  second  developmental  week  which  juxtaposes  with  a
developmental upregulation of GluN2A. In  chapter 5,  the role of the GluN2 C-
terminus in this process will be investigated. 
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1.3 NMDAR pharmacology
The drugs used to alter NMDAR properties pertaining to this thesis are summarized
in table 1.3.  
Drug Site of
Action









































GluN2A population with a




















can be superseded by
increasing agonist
concentration.  
 TCN 213 (30 µM) and TCN
201 (10  µM) selectively
inhibit GluN2A over
GluN2B. 
Table 1.3 : Summary of NMDAR antagonists relevant to this thesis. See (Paoletti &
Neyton 2007) for an extensive review.
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1.3.1 (+)/- MK-801
MK-801 was developed as an anticonvulsant and was later found to be an NMDAR
antagonist  (Wong et al. 1986). MK-801 is “use dependent” meaning it only blocks
NMDARs which are in the open state induced by agonist binding (Huettner & Bean
1988). Both by patch clamp recordings (Huettner & Bean 1988) and by radioligand
binding assays  (Reynolds & Miller 1988) it was noted that Mg2+ inhibits MK-801
binding.  This  suggests  that  MK-801  has  an  overlapping  binding  site  with  Mg2+
somewhere  in  the  channel  pore.  This  was  later  confirmed  by  site  directed
mutagenesis where mutations, such as N616Q in the M2 loop of the GluN1 subunit,
abolished inhibition by both Mg2+ and MK-801 (Kashiwagi et al. 2002) .
MK-801 has a very slow off-rate as it requires the NMDAR channel to be open ; in
other  words,  the  recovery  from the  MK-801  block  is  also  use  dependent.  This,
combined with  a  reported  time constant  for  recovery of  92±106min (mean±SD)
(Huettner  &  Bean  1988)  led  to  MK-801  being  labelled  as  an  “irreversible
antagonist.” However,  the time constant calculated was determined using 30 µM
NMDA; if a higher concentration of NMDA was used then the open probability of
the NMDAR would increase ultimately resulting in a decrease in the time constant.
Furthermore, the large standard deviation suggests some cells had a faster recovery
than others perhaps because of insufficient washout of MK-801. Critically, although
it  is  established  Mg2+ inhibits  MK-801  binding,   the  effects  of  Mg2+ on  the
dissociation of MK-801 had yet to be investigated; the determination of this will be
the  main  focus  of  chapter 3  and  the  relevance  of  this  eluded  to  the  upcoming
sections regarding establishing the role of the NMDAR in mediating excitotoxicity. 
As MK-801 is extremely potent, unlike Mg2+, MK-801 is not suitable to discriminate
between 2A/2B and 2C/2D subunit types. At pH 7.6, all four subunits have an IC50
in the range of  9–38 nM  (Dravid et al. 2007). MK-801 also shows antagonism at
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nicotinic acetylcholine receptors (nACHRs) (Briggs & McKenna 1996; Ramoa et al.
1990)  in addition to inhibiting serotonin (Iravani et al. 1999) and dopamine (Clarke
& Reuben 1995) transporters.
1.3.2 Protons
Protons are an endogenous negative allosteric modulator of NMDARs(Traynelis et
al. 1995; Low et al. 2003) .  Polyamines (Traynelis et al. 1995)  and zinc (Low et al.
2000) (in an allosteric modulator manner)  enhance proton sensitivity.     
1.3.3 Memantine
Memantine is also an open channel blocker of the NMDAR ; the N616Q mutation
described above also abolishes memantine potency confirming it has an overlapping
binding site with both Mg2+ and MK-801 (Kashiwagi et al. 2002). Unlike MK-801,
memantine has a very high off-rate in the absence of Mg2+ and is the main proposed
reason why it is well tolerated clinically compared to antagonists with a slower off
rate  (Chen et al. 1992). In the presence of Mg2+, memantine preferentially inhibits
GluN2C/GluN2D over GluN2A/GluN2B under steady state glutamate application
(Kotermanski  & Johnson 2009).  Additionally, Otton et  al.  2011 demonstrate  that
inhibition of GluN2A containing NMDARs by memantine is drastically reduced in
the presence of Mg2+. 
It  will  be  elaborated  in  a  further  section  regarding  the  therapeutic  uses  of
memantine, and the proposed mechanisms,  but it should be stressed that memantine
has  off-target  effects  including antagonism at  5-HT(3)  receptors  (Rammes  et  al.
2001) and nACHRs  (Aracava et al. 2005; Buisson & Bertrand 1998) with additional
agonist action at dopaminergic (D2) receptors (Seeman et al. 2008). 
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1.3.4 Ifenprodil
Ifenprodil is an allosteric modulator with a 400-fold selectivity for GluN2B (IC50 =
0.34 µM) over GluN2A (IC50 = 146  µM) (Williams 1993). Ifenprodil is commonly
used  at  3  µM  which  inhibits  GluN2B  containing  NMDAR  by  80%.  At  higher
concentrations, it has been noted that ifenprodil has an IC50 of 10  µM at presynaptic
P/Q type Ca2+ channels (Delaney et al. 2012) but as ifenprodil has been used at 3 µM
throughout  this  thesis,  the  effects  will  be  negligible.  Ifenprodil  inhibits
triheteromeric NMDARs by approximately 30% under  constant  agonist  exposure
(Hatton & Paoletti 2005; Hansen et al. 2014).
1.3.5 NVP-AAM077
NVP-AAM077 was  originally  characterized  in  a  heterologous  Xenopus oocyte
system expressing human NMDARs. NVP-AAM077 was found have a  >100 fold
preference for inhibiting NMDARs containing GluN2A over GluN2B (Auberson et
al.  2002). However, this and other studies  Liu et al.  (2004a),  failed to take into
consideration that as GluN2A and GluN2B have different affinities for glutamate,
and as NVP-AAM077 acts as a competitive antagonist, its potency is dependent on
the concentration of glutamate present at the NMDAR. 
To resolve this, IC50 values for NVP-AAM077 were calculated at the EC50 values for
glutamate at the GluN1/GluN2A and GluN1/GluN2B NMDARs for rat NMDARs ;
NVP-AAM077 was  found  to  be  only  ~5-fold  more  selective  for  GluN2A than
GluN2B when glutamate is at the respective EC50  (Frizelle et al. 2006; Neyton &
Paoletti  2006).  Repeating  this  more  robust  approach  to  determine  selectivity  at
human NMDARs would be fruitful as it would determine if there is any species
difference in NVP-AAM077 potency. 
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The importance of the above in selectively blocking GluN2A containing NMDARs
is elegantly demonstrated by the implementation of GluN2A knockout  mice.   In
matureGluN2A-/- CA1 pyramidal cells,  NVP-AAM077 block of approximately 20%
of an EPSC is observed when used at 50nM but if increased 8-fold to 400nM, it
blocks  approximately  60%  (Berberich  et  al.  2005).  Therefore,  despite  NVP-
AAM077 at 400 nM being unsuitable to selectivity inhibit GluN2A, it has been used
at this concentration to investigate synaptic plasticity and excitotoxicity which shall
be elaborated in  a  subsequent  section.   Additionally,   NVP-AAM077 acts  as  an
antagonist at GluN2C and GluN2D containing NMDARs (Feng et al. 2004). 
1.3.6 Zinc 
In  the  nanomolar  range,  zinc acts  as  an  allosteric  modulator  to  inhibit  GluN2A
containing  NMDARs  with  little  antagonism  of  GluN2B  containing  NMDARs
(Paoletti et al.  1997). At higher concentrations, zinc acts as an NMDAR channel
blocker where it antagonizes both diheteromeric GluN2A and GluN2B containing
NMDARs. In the nanomolar range, maximal inhibition by zinc has been determined
to be 80% for a diheteromeric GluN2A population and 14% for GluN2A-GluN2B
triheteromeric NMDARs (Hatton & Paoletti 2005). Such a loss of zinc antagonism
at GluN2A-GluN2B NMDARs was not reported by (Hansen et al. 2014); at pH 7.3,
a  maximum inhibition  of  59% and  49% maximum inhibition  was  observed  for
diheteromeric GluN2A and triheteromeric GluN2A-GluN2B NMDARs respectively.
Interestingly,  a  triheteromeric  population  containing  one  WT  GluN2A and  one
GluN2A with the zinc binding site mutated had a marked decrease in zinc potency
compared  to  triheteromeric  GluN2A-GluN2B  NMDARs.  To  explain  such  an
observation, it is clear further research is needed to explain zinc modulation fully. 
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1.3.7 TCN 201 and TCN 213
TCN  201  and  TCN  213  were  identified  as  selective  antagonists  for  GluN2A
containing NMDARs by a Ca2+ imaging screen (Bettini et al. 2010). Subsequently,
TCN 201 and TCN 213 were found to  allosterically modulate,  via the GluN2A
subunit,  glycine/D-serine binding at the GluN1 subunit (McKay et al. 2012; Edman
et  al.  2012;  Hansen  et  al.  2012).  Therefore,  the  IC50 of  these  compounds  are
dependent  on  the  concentration  of  either  glycine  or  D-serine  at  the  NMDAR.
Further studies revealed that Val783 in the S2 segment of the agonist binding site on
GluN2A subunit is critical in the binding of TCN 201 (Hansen et al. 2012).
The main focus of chapter 4 will be determining the ability of these compounds to
antagonize  endogenously expressed  GluN2A-containing  NMDARs in  rat  cortical
cultures. 
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1.4 Neuroprotective and neuronal death signalling
Although  on  the  surface  it  seems  paradoxical  that  NMDARs  can  mediate  both
neuroprotection and neuronal death, the subsequent section will discuss the complex
signalling by NMDARs which makes this possible. 
1.4.1 Excitotoxicity mediated by NMDARs
1.4.1.1 Introduction to excitotoxicity
Over 50 years ago,  (Lucas & Newhouse. 1957) observed that subcutaneous doses of
glutamate caused widespread degeneration in the inner retina of mice. Additionally,
subcutaneous  doses  of  glutamate  was  noted  to  cause  degeneration  in  the
hypothalamus of rats  (Olney 1969) and Olney coined the term “excitotoxicity” to
describe  the  toxic  effects  of  glutamate.  Further  in  vitro studies  of  retinal  slices
demonstrated that NMDAR activation alone was sufficient to induce excitotoxicity
and could be blocked by NMDAR antagonists  (Olney et  al.  1986).  Furthermore,
occlusion of the carotid artery induces ischemic conditions and causes excitotoxicity
in the hippocampus; focal infusion of an NMDAR antagonist into the hippocampus
before  this  insult  dramatically  reduces  excitotoxicity  (Simon  et  al.  1984).
Altogether,  this  suggests  NMDARs are  the  predominate  glutamate  receptor  that
mediate excitotoxicity in vivo.  
Neuronal in vitro cultures were noted to recapitulate the excitotoxicity of in vivo and
in vitro slice studies  (Choi 1987a; Choi et al. 1987b; Choi et al. 1988) permitting
dissection  of  the  molecular  mechanisms  underlying  excitotoxicity.  Subsequent
studies utilizing high tonic glutamate or NMDA has revealed that excitotoxicity is
controlled via complex and interrelated signalling cascades summarized in  Figure
1.5.
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Figure 1.5: Signalling cascades induced by high tonic glutamate.   High tonic
glutamate  can  result  from  ischemic  insults,  traumatic  brain  injury  or  certain
neurodegenerative diseases. High tonic glutamate leads to a Ca2+ influx that activates
pro-death  signalling  cascades.  This  includes  a  collapse  of  the  mitochondrial
membrane  potential,  a  decrease  in  the  activity  of  pro-survival  gene
expression/protein activity and finally, an increase in the activity of calpains. Such
signalling can lead to neuronal apoptosis.  
1.4.1.2 Spatial signalling of NMDARs and excitotoxicity
Of great interest was the Ca2+ source specificity in mediating excitotoxicity. This
was first  addressed by  (Tymianski et  al.  1993) where it  was noted that although
depolarization and bath application of glutamate could evoke similar Ca2+ somatic
influxes,  glutamate  preferentially induced excitotoxicity.  Similarly,  depolarization
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and bath glutamate was found to activate  transcription of  c-fos but  via  different
promoter  elements  (Bading  et  al.  1993).  Furthermore,  it  was  demonstrated  that
cytoplasmic and nuclear Ca2+ must be thought as distinct biochemical compartments
in neurons as they can control distinct transcriptional pathways (Hardingham et al.
1997). Ca2+ influx via synaptic activation of NMDARs promotes further Ca2+ release
from  intracellular  stores  resulting  in  a  nuclear  Ca2+ wave  sufficient  to  activate
CREB-mediated  transcription  without  the  need  for  cytoplasmic  proteins
(Hardingham  et  al.  2001).  However,  bath/tonic  application  of  glutamate  which
activates both synaptic and extrasynaptic NMDAR results in CREB shut-off which
is a key mediator of excitotoxicity (Hardingham et al. 2002). As synaptic activity
strongly activated synNMDARs and promoted CREB activation,  it  was proposed
that exNMDARs may preferentially shut-off CREB. However, there is a temporal
difference between synaptic activation of synNMDARs and tonic activation of both
synNMDARs and exNMDARs. 
To  further  test  the  hypothesis  that  exNMDARs  are  preferentially  coupled  to
excitotoxicity,  it  would  be  necessary  to  isolate  the  two  spatial  populations  and
measure  a  key  component  of  excitotoxicity.  To  pharmacologically  isolate
exNMDARs,  (Hardingham et al. 2002) drove synaptic activity in the presence of
MK-801 to  block synNMDARs;  once  this  blockade was  complete  and MK-801
washed  out,  exogenous  glutamate  could  be  added  to  preferentially  activate
exNMDARs. This approach is shown graphically in Figure 1.6. 
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Figure 1.6: Blockade of synNMDARs with MK-801.  SynNMDARs can selectively be
blocked by promoting bursts of synaptic activity in the presence of MK-801. After washout
of MK-801, exNMDARs can be selectively activated by bath applying exogenous glutamate
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Measuring for depolarization of mitochondrial membrane potential, a key factor in
excitotoxicity (Qiu et al. 2013), juxtaposed with the above approach revealed details
of spatial signalling by NMDARs. Firstly, synaptic activity fails to impact on the
mitochondrial  membrane  potential  which  is  in  agreement  with  synaptic  activity
being  neuroprotective  (discussed  below).  Secondly,  selective  activation  of
exNMDARs was sufficient to depolarize mitochondria suggesting exNMDARs may
indeed  preferentially  couple  to  excitotoxicity.  Furthermore,  utilizing  an  electron
probe  micro-analyzer,  (Stanika  et  al.  2009) determined  that  although  bath
application of NMDA caused 3.6 times more Ca2+ in the cytoplasm compared to
synaptic activation by bicuculline, at the mitochondria there was 155-fold increase
in Ca2+; this confirms that is not simply the Ca2+ load that dictates Ca2+ mediated
mitochondrial dysfunction.   
One possible explanation for this  phenomenon is  that although mitochondria are
strongly expressed in dendrites where they play a critical role in spine development
and plasticity, they are very rarely expressed in dendritic spines or filopodia (Li et al.
2004). Therefore,  as mitochondria are largely located extrasynaptically, they may be
better spatially located to buffer toxic Ca2+ influx during an excitotoxic insult. 
It is important to stress that the above experiments do not prove that exNMDARs
exclusively mediate  excitotoxicity  but  rather  there  is  strong evidence  to  suggest
exNMDARs  may  preferentially  couple  to  excitotoxicity.  As  discussed  prior,
memantine is an open channel blocker with an off-rate which is suitable for blocking
high tonic levels of glutamate but spares blocking physiological levels of synaptic
activity  (Lipton  2006).   Recent  studies  claim  memantine  preferentially  blocks
exNMDARs  (Xia  et  al.  2010;  Okamoto  et  al.  2009) yet  the  design  of  these
experiments do not support this conclusion; exNMDARs were isolated using the
MK-801 approach discussed above and 10 µM memantine was found to strongly
block tonic activation of these receptors. However, if the experiment was repeated
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with  attempting  to  block both  synaptic  and  extrasynaptic  NMDARs under  tonic
activation then a similar level of block would be observed  (Wrighton et al. 2008;
Wroge  et  al.  2012;  this  thesis).  Therefore,  from these  studies,  it  is  evident  that
memantine  would only preferentially block exNMDARs if  synaptic  activity was
preserved at the synapse whilst simultaneously there was high tonic glutamate at
extrasynaptic sites; to what extent this occurs in vivo is not clear. Furthermore, it is
now  established  that  memantine  can  block  low  frequency-evoked  synaptic
NMDARs in  Mg2+-free  ACSF  utilizing  autaptic  cultures  (Wroge  et  al.  2012).
Furthermore, in low 0.1 mM Mg2+, memantine can block NMDAR-EPSCs at high,
but not low, frequency-evoked synaptic NMDARs (Wild et al. 2013). To summarize,
the neuroprotective effects of memantine should not solely be attributed blocking
exNMDARs  but  rather  the  temporal  profile  of  glutamate  activating  both
synNMDARs and exNMDARs should be considered. 
The hypothesis that exNMDARs are preferentially coupled to excitotoxicity is not
absolute;  evidence  exists  for  synaptic  NMDARs  exclusively  mediating
excitotoxicity  (Wroge et al. 2012; Papouin et al. 2012)  whilst additionally, it has
been  proposed  that  co-activation  of  both  synaptic  and  extrasynaptic  NMDARs
mediate excitotoxicity (Zhou et al. 2013) as summarized in Figure 1.7. The studies
of Wroge et al and Zhou et al.  utilized MK-801 to block synNMDARs in an attempt
to selectively activate exNMDARs. However, rather than measure immediate effects
such as mitochondrial depolarization, they attempted to induce neuronal death itself.
This of course requires synNMDARs to be selectively blocked by MK-801 for a
greater length of time yet it is unclear if MK-801 would stably block synNMDARs
under these conditions. If MK-801 is proven to be unstable, it would subsequently
be difficult to interpret the results of Wroge et al and Zhou et al. 
Therefore,  an  attempt  to  resolve  the  conflicting  hypotheses  regarding  source
specificity  in  NMDAR-dependent  excitotoxicity will  be  made  in  chapter  3  by
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determining the stability of the MK-801 block under  tonic agonist  exposure and
physiologically concentrations of Mg2+. 
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Figure  1.7: Source  specificity  in  NMDAR-dependent  excitotoxicity.  NMDAR
mediated  excitotoxicity  can  theoretically  occur  by  three  distinct  spatial  routes:
synNMDARs  alone,  exNMDARs  alone  or  a  combination  of  synNMDARs  and
exNMDARs. 
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1.4.2 Neuroprotective signalling by synaptic activity
The  concept  that  NMDAR  activation  under  physiological  conditions  may  be
beneficial  was  first  proposed  by  Olney;  he  noted  that  NMDAR  antagonists
administered  subcutaneously  to  rats  could  induce  large  vacuoles  containing
mitochondria in posterior cingulate neurons  (Olney et al. 1989). Subsequently,  it
was  demonstrated  perinatal  antagonism  of  NMDARs  could  induce  widespread
apoptosis (Ikonomidou et al. 1999) and exacerbate neuronal death induced by head
trauma (Pohl et al. 1999). Great strides in the last 15 years have dissected out the
molecular mechanisms underlying neuroprotective signalling by synaptic activity as
summarized in Figure 1.8.  
Figure  1.8: Synaptic  activity  is  neuroprotective. Increasing  synaptic  activity
promotes  Ca2+ influx at  synNMDARs with little  activation of  exNMDARs.  This
temporal  and  spatial  activation  promotes  anti-apoptotic  genes  expression,
antioxidant  defences  and mitochondrial  health.  In addition to  promoting survival
pathways,  synaptic  activity  also  dampens  pro  death  signalling  pathways  by
decreasing pro-apoptotic gene expression. 
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As discussed in the previous section, synaptic activity results in the activation of
CREB  via  nuclear  Ca2+.  Specifically,  nuclear  CaM  kinase  is  activated  and
phosphorylates  CREB  at  ser133  which  in  turn  promotes  the  binding  of  CREB
binding  protein  (CBP);  CBP is  then  subsequently phosphorylated   at  ser301  by
CaMKIV finally  permitting  the  transcription  of  certain  genes  which  have  CRE
region (Wu et al. 2001).  CREB can regulate  “activity-regulated inhibitors of death
(AID)” genes which converge to boost mitochondrial health and thus leave neurons
less vulnerable to excitotoxicity  (Zhang et al. 2009).  Only 1 of the 9 AID genes,
NPAS4, was found not to be a CREB target gene which stresses the importance of
CREB regulated gene expression. Incidentally, NPAS4 has subsequently been shown
to be critical in regulating mitochondrial health (Qiu et al. 2013). 
Ca2+ influx via NMDARs can also activate CREB in a slower, indirect mechanism
by activating  ERK.  Fascinatingly,  glutamate  uncaging  (1Hz,  60  secs)  at  only  7
dendritic spines can activate ERK sufficiently to detect CREB phosphorylation of
ser133 (Zhai et al. 2013). Although the physiological relevance of this is unclear as
the experiments were conducted in the absence of Mg2+, it clearly demonstrates that
even  small  synaptic  Ca2+ transients  have  the  potential  to  be  neuroprotective.
Furthermore,  when dendritic and somatic Ca2+ are buffered,  it  is still  possible to
activate ERK by Ca2+ influxes via synaptic NMDAR; this suggests a local pool of
Ca2+ in  the  direct  vicinity  of  the  NMDARs should  be  thought  as  biochemically
distinct from that in the dendrites and soma (Hardingham et al. 2001a).
In  addition  to  dampening  down  pro-apoptotic  signalling,  synaptic  activation  of
CREB  can  also  promote  pro-survival  gene  expressions  such  as  brain-derived
neurotrophic  factor  (BDNF).  BDNF  is  neuroprotective  and  can  mitigate  the
detrimental  effects  of  blocking  synaptic  activity  (Hansen  et  al.  2004).  Synaptic
activity also boosts anti-oxidant defences leaving neurons more resistant to oxidative
stress (Papadia et al. 2008). 
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1.4.3  GluN2  subtype  and  coupling  to  neuroprotection  and  excitotoxicity
signalling
It  has  been  reported  that,  independent  of  membrane  location,  GluN2A mediates
neuroprotective signalling whilst GluN2B mediates excitotoxicity (Liu et al. 2007a).
However, this study derives many of the conclusions from experiments where NVP-
AAM077 would not selectively block GluN2A but would also block a significant
portion  of  GluN2B  NMDARs.  Another  study  utilizing  a  more  appropriate
concentration of NVP-AAM077 concluded that in mature neurons both GluN2A and
GluN2B mediate excitotoxicity; an additive effect of ifenprodil and NVP-AAM077
was observed in blocking excitotoxicity (von Engelhardt et al. 2007). Furthermore,
in young neurons that predominately express only the GluN2B subunit, NMDARs
can still mediate neuroprotective and excitotoxic signalling. This suggests it is the
location of the NMDAR/temporal profile of glutamate which dictates whether the
NMDAR couples to neuroprotective or excitotoxic signalling in this instance (M-A
Martel  et  al.  2009).  GluN2B  and  GluN2A mediating  both  neuroprotection  and
excitotoxicity has also been reported (Stanika et al. 2009). 
As  previously  discussed,  the  CTD  of  GluN2A  and  GluN2B  have  diverged
significantly in order to couple to different signalling cascades; it was hypothesized
that any potential differences in excitotoxicity may be down to differences in the
CTDs. To address this, chimera constructs were designed where the GluN2A CTD
was swapped with that  of GluN2NB (named GluN2A2B(CTR))  and the reciprocal
GluN2B  CTD  with  the  GluN2A  CTD  (named  GluN2B2A(CTR)). When  these
constructs were transfected into neurons,  it  was observed that  the GluN2B CTD
promoted excitotoxicity whether coupled to the GluN2A or GluN2B subunit (Martel
et al. 2012); this suggests both GluN2A and GluN2B can both mediate excitotoxicity
but  the  CTD  of  GluN2B  induces  a  stronger  insult.  Furthermore,  cultures  from
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genetically modified mice where the GluN2B CTD had been replaced with that of
GluN2A, were created. Under similar Ca2+ loads to WT cultures, the GluN2B2(ACTR)
cultures  were  less  vulnerable  to  excitotoxicity,  confirming  the  GluN2B  CTD
preferentially  couples  to  excitotoxicity.  Importantly,  such  findings  were
recapitulated in vivo. Interestingly, the detrimental effects of the GluN2B CTD could
be overcome by increasing concentrations of agonist; this suggests that under high
Ca2+ influx the CTD becomes irrelevant possibly because the toxic effects of Ca2+ at
mitochondria is saturated and cannot be further enhanced by intracellular signalling
by the NMDAR. 
There are several mechanisms by which the CTD of GluN2B may preferentially
couple to excitotoxicity. Firstly,  a cell-permeable peptide mimetic of the GluN2B
PDZ ligand (NA-1/Tat-NR2B9c) disrupts the interaction of the GluN2B CTD and
PSD-95  (Aarts  et  al.  2002).  Under  excitotoxic  conditions,   NA-1/Tat-NR2B9c
uncouples the GluN2B from nitric oxide production which ultimately has the effect
of dampening down pro-death p38 signalling and CREB shut-off  (Soriano et  al.
2008; Martel et al. 2012). From a clinical perspective, it is promising that NA-1/Tat-
NR2B9c has the beneficial effect of not only reducing lesion size but also improving
general  outcome  of  non  human  primates  post  stroke  (Cook  et  al.  2012).
Furthermore, NA-1/Tat-NR2B9c was found to reduce lesion size  12-95 hours after
infusion in a phase II aneurysm trial (Hill et al. 2012).  Other studies have linked the
GluN2B  C-terminal  domain  to  excitotoxicity.  Death-associated  protein  kinase  1
(DAPK1) phosphorylates ser1303 on the CTD of GluN2B which increases NMDA
currents and thus excitotoxicity; a peptide which blocks DAPK1 interaction with the
CTD was shown to be neuroprotective in vivo (Tu et al. 2010). 
A  study  utilizing  cultures  derived  from  genetically  modified  mice  where  the
GluN2A CTD  had  been  replaced  with  that  of  GluN2B  (the  opposite  genetic
modification to that in the Martel  (2012) study)  will  be the focus of  chapter 5;
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evaluating the role of the GluN2 CTD in excitotoxicity and neuroprotection will be
expanded here. 
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1.5 NMDAR-dependent synaptic Plasticity
The earliest evidence that NMDARs are necessary for some forms of memory  in
vivo was  derived  from a  pharmacological  approach;  administration  of  NMDAR
antagonists prevented spatial learning with no effect on visual learning (Morris et al.
1986). Since then, a great body of work has attempted to elucidate the molecular
processes involved in learning & memory; it should be stressed that is beyond the
scope of this thesis to discuss in any great detail the intricacies of such processes
which will vary greatly between brain regions. 
Nevertheless,  synaptic  plasticity,  the ability of synapses to  strengthen or weaken
their connections, supports Hebbian theory. The two most studied forms of synaptic
plasticity  are  long  term  potentiation  (LTP)  and  long-term  depression  (LTD)
(Malenka & Bear 2004). NMDAR dependent LTP is induced by a short but high
frequency stimulation of a presynaptic pathway ultimately resulting in a high level
of Ca2+ influx via NMDARs; this postsynaptic Ca2+ activates certain kinases which
promotes  the  insertion  of  AMPAR into  the  synapse  thus  causing  an  increase  in
synaptic strength. It has been widely proposed that this was AMPAR subunit specific
with the GluA1 CTD being critical  for this insertion  (Kessels & Malinow 2009,
Anggono & Huganir 2012). However, replacement of the GluA1 subunit with the
GluA2  subunit  and  even  more  surprisingly,  a  kainate  receptors  (which  are  not
endogenously  expressed  hippocampal  pyramidal  neurons),  showed  normal  LTP
(Granger et al. 2013). If such findings are replicated, a paradigm shift from the view
that  changes  in  the  trafficking  of  GluA1  containing  AMPA receptor  being  the
predominant mechanism underlying LTP, may be needed. 
On the other hand, NMDAR dependent LTD is achieved by a sustained but lower
Ca2+ influx  via  NMDAR;  now,  this  postsynaptic  Ca2+ favours  the  activation  of
phosphatases which promote the retrieval of AMPA receptors at the synapse. It has
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been proposed that NMDAR may mediate LTD through a metabotropic mechanism
(Nabavi et al. 2013; Kessels et al. 2013) but this has since been refuted (Babiec et al.
2014). 
1.5.2 NMDAR subunit-specific contributions to LTP and LTD
A long-standing hypothesis is that due to subtle differences in biophysical properties
of GluN2A and GluN2B, coupled to their divergent CTDs, one GluN2 subunit may
mediate  LTD  and  the  other  LTP.  However,  the  data  is  contradictory  especially
regarding LTD (Shipton & Paulsen 2014). Much of this controversy is due to the use
of  the  NVP-AAM077 (previously discussed)  and confounded by the problem of
compensatory  mechanisms  induced  by  genetic  knock-out  of  whole  subunits.
Furthermore,  as  previously  discussed,  there  is  increasing  evidence  that  a
triheteromeric GluN2A-GluN2B population exists which was a critical  factor not
included in the original hypothesis. 
As previously discussed, truncating the C terminal domain of GluN2A and GluN2B
alters  channel gating but reciprocally switching the CTD domains has no effect.
Therefore, where genetic truncation of the CTD of GluN2 subunits has resulted in
deficits in synaptic plasticity (Sprengel et al. 1998; Moody et al. 2011) it is difficult
to determine if this was due to uncoupling of the NMDAR to signalling cascades or
changes in the biophysical properties of the NMDAR. To address this,  a genetic
approach  identical  to  that  discussed  in  section  1.4.3 was  utilized  to  investigate
hippocampal LTP; the C terminal domains of the GluN2A and GluN2B subunits
were reciprocally swapped. When the CTD of GluN2A was replaced with GluN2B,
no deficits  in LTP induced by both theta-burst  and theta-pulse stimulations were
observed. Conversely, when the CTD of GluN2B was replaced with that of GluN2A,
there was now enhanced theta-burst LTP but suppressed theta-pulse LTP (Ryan et al.
2013). This suggests that GluN2B preferentially promotes certain forms of LTP via
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its CTD.  It has been proposed the GluN2B subunit may have a preferential role in
LTP through its interaction with CaMKII  (Nicoll & Roche 2013; Halt et al. 2012). 
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1.6 The role of the NMDA Receptor in Pathological conditions
As  discussed  heavily  in  section  1.4,  the  NMDAR is  critical  in  mediating  both
neuronal  protection  and  neuronal  death.  Therefore,  it  is  not  surprising  that  the
NMDAR has founds to be involved in the pathology of diseases where neuronal loss
is  observed,  including  several  neurodegenerative  diseases  and  conditions  where
ischemic brain damage is  present.  An overarching role  of  the NMDAR in these
conditions appears to be a promotion of neuronal death signalling (rather than a lack
of  neuroprotective  signalling)  but  such  reductionists  views  should  be  avoided.
Indeed, a long-held hypothesis pertaining to the use of NMDAR antagonists to aid
the treatment of stroke was rejected after an increase in mortality was observed in
clinical trials (Davis et al. 2000). It is now hypothesized that the lack of efficacy in
the trial was because excitotoxicity at the primary injury site is particularly rapid,
and consequently,  the  NMDAR antagonism was  too  late  in  preventing  neuronal
death.  On the other hand,  it  has been proposed that  NMDAR antagonism at the
secondary  site  dampened  pro-survival  signalling  thus  resulting  in  the  increased
mortality.  Therefore,  when designing a  therapeutic  strategy aimed at  altering the
function of the NMDAR,  it  is imperative to consider the multifaceted nature of
NMDAR signalling.  
Below  is  a  summary  of  several  pathological  conditions  where  the  NMDAR
contributes  to  the  diseased  state.  This  inclusion  is  not  intended  to  be  either
exhaustive  or  comprehensive,  but  rather  serves  to  highlight  the  far-reaching
implications of study basic NMDAR function. 
1.6.1 Huntington's Disease
Huntington's  disease  is  a  neurodegenerative  disorder  with  a  strong  genetic
component; polyglutamine repeats in the Huntingtin gene cause an expansion of the
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N terminus  of  the  protein  ultimately  resulting  in  a  toxic  gain  of  function.  The
toxicity initiates strongly in the striatum but spreads to to other brain regions as the
disease progresses. A mouse model of Huntington's disease shows enhanced NMDA
dependent excitotoxicity which is abolished by a GluN2B antagonist  (Zeron et al.
2002), This model was later shown to have a higher proportion of extrasynaptic
NMDARs (Milnerwood et al. 2010) which has been recapitulated in cultures acutely
expressing the mutant  Huntingtin protein  (Puddifoot et al.  2012).  Memantine has
been shown to delay the progression of Huntington's disease but as the trial was
small, it is imperative this is repeated before any definitive conclusions are made
(Beister et al. 2004). 
1.6.2 Alzheimer's Disease
Unlike  Huntington's  disease,  the  pathophysiology  of  the  neurodegenerative
Alzheimer's disease (AD) is extremely controversial and is beyond the scope of this
thesis. Soluble oligomers of amyloid β (Aβ), a hallmark of the disease,  can induce
synaptic dysfunction mediated through the NMDAR as measured by a loss of PSD-
95  (Roselli  et  al.  2005) and  spine  number  (Shankar  et  al.  2007) in  mice.
Furthermore, Aβ can facilitate NMDAR-dependent LTD (Li et al. 2009) and inhibit
LTP (Li et al. 2011). Importantly, recent evidence has managed to link Aβ with Tau
and cellular prion proteins (PrPC), other hallmarks of the diseases, via the NMDAR.
Both tau (Ittner et al. 2010) and PrPC (Um et al. 2012) have been shown to enhance
Fyn interacting with the NMDAR; as phosphorylation of Y1472 by Fyn prevents
AP-2  mediated  endocytosis,  this  will  disrupt  regulation  of  NMDAR  surface
expression,  thus  having  the  ultimate  consequence  of  enhancing  Aβ  toxicity.
Furthermore, PrPC  can modulate the glycine/D-serine affinity of the NMDAR in a
Cu2+-dependent manner; Aβ can disrupt this physiological function of PrPC leading to
an excessive and toxic Ca2+ influx caused by a dysregulation of desensitization (You
et al. 2012).
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Memantine was found to be beneficial in treating mild to severe AD (Reisberg et al.
2003) but  a  re-assessment  of  three  trials,  including 431 patients  with  mild  AD,
concluded that there is a lack of evidence for the beneficial effects of memantine
(Schneider  et  al.  2011).  Furthermore,  as  previously  discussed,  memantine  has
pharmacological  effects  at  5-HT(3)  receptors,  nACHRs  and  dopaminergic  (D2)
receptors. 
1.6.3 Ischemic brain damage induced by stroke or traumatic brain injury
As discussed earlier in this introduction, ischemic conditions can lead to high levels
of  glutamate  and  eventually  excitotoxicity.  This  is  because  ischemic  conditions
cause  a  reduction  in  cellular  ATP  levels  thus  disrupting  the  function  of
Na+/K+-ATPase  ultimately  leading  to  the  collapse  of  cellular  Na+ gradients.  As
glutamate transporters are secondary active transporters relying on the Na+ gradient,
glutamate uptake is impaired or under severe instances, can even reverse (Camacho
& Massieu 2006). Altogether, this leads to an accumulation of glutamate at synaptic
and extrasynaptic sites which leads to overactivation of NMDARs. 
1.6.4 Epilepsy and neuropsychiatric disorders
Mutations in Grin2a and Grin2b can result in intellectual disability, epilepsy and
autism  (Endele  et  al.  2010;  O’Roak  et  al.  2012;  Talkowski  et  al.  2012).  Such
mutations can drastically alter the function of the NMDAR. For example, a patient
with early-onset epileptic encephalopathy  was found to have a   de novo missense
mutation (L812M) in grin2a. This mutation altered agonist potency, Mg2+ sensitivity
and open probability of the NMDAR (Yuan et al. 2014).  
The aetiology of schizophrenia is highly complex yet nevertheless, there is an over-
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abundance of evidence which suggests a strong NMDAR hypofunction component.
Ketamine  is  known  to  induce  both  the  positive  and  negative  symptoms  of
schizophrenia in humans  (Krystal  et  al.  1994) and administration of ketamine to
mice  results  in  elevated  motor  activity  and  deficits  in  social  interactions;
importantly,  genetically  reducing  NMDAR  expression  in  mice  recapitulates  the
ketamine-induced behaviours  (Mohn et al. 1999). Currently, a great deal of research
is aimed at treating NMDAR hypofunction by pharmacologically enhancing NMDA
function via the glycine binding site (Chang et al. 2014). 
Lastly,  a  recently  characterized  disease,  anti-NMDA-receptor  encephalitis,
demonstrates that acute perturbation of NMDAR function in adulthood can have
profound  pathophysiological  consequences.  Here,  an  acute  autoimmune  reaction
against GluN1 induces a decrease in the surface density and synaptic localization of
the NMDAR  (Hughes et al.  2010) which ultimately manifests itself in symptoms
inlcuding memory impairment, psychosis and seizures (Dalmau et al. 2008). 
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1.7 Experimental Hypotheses 
It  is  evident  from  this  introduction  that  the  biological  outcome  of  NMDAR
activation  is  determined  by  a  complicated  interrelationship  between  the
concentration of Ca2+ influx, NMDAR location (synaptic vs. extrasynaptic) as well
as the subtype of the GluN2 subunit. Despite the recognition that NMDAR mediated
physiology  is  multifaceted,  tools  used  to  study  subunit  and  location  dependent
signalling are poorly characterized and in other cases, non-existent. Therefore, the
aim of this thesis is to address this issue. 
In chapter 3, I attempt to resolve conflicting hypotheses regarding how the spatial
location of NMDARs determines the ability of NMDARs to couple to excitotoxic
signalling. In section 1.3.1, I highlighted that Mg2+ can inhibit MK-801 binding to
the NMDAR but it was currently unknown how Mg2+ would effect the dissociation
of MK-801. Furthermore, I highlighted in  section 1.4.1  that MK-801 blockade of
synNMDARs must  be  stable  in  order  for  selective  activation  of  exNMDARs to
occur. Therefore, I questioned what would be the consequence if Mg2+ promotes the
dissociation of MK-801? Ultimately, this would render blockade of synNMDARs
unstable,  calling  into  question  the  validity  of  long-term  selective  exNMDAR
activation.  Therefore,  I  re-assessed  MK-801  pharmacology  in  the  presence  of
physiologically concentrations of Mg2+ and found MK-801 is not irreversible under
constant agonist exposure. The relevance of this finding is that it confines a temporal
limit in which selective activation of extrasynaptic NMDARs can occur; I will re-
asses previous findings in this new light in the upcoming discussions. 
Dissecting subunit-dependent signalling mediated by the two major GluN2 subunits
in the forebrain, GluN2A and GluN2B, has been advanced significantly by selective
GluN2B antagonism yet a reciprocal GluN2A selective antagonist has been lacking
as  discussed in  section 1.3.5.  Therefore,  in  chapter 4,  I  utilized  novel  GluN2A
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antagonists (TCN 201 and TCN 213) to question whether these compounds could
detect a developmental upregulation of GluN2A in cortical cultures.  Young neurons
were  highly  sensitive  to  the  selective  GluN2B  antagonist  ifenprodil  but  were
insensitive to TCN 201 & TCN 213. However, in older neurons and young neurons
overexpressing GluN2A, a reduced sensitivity to ifenprodil and enhanced sensitivity
to TCN 201 and TCN 213 was observed. Under certain conditions, young GluN2A
transfected  neurons  show  a  stronger  inhibition  by  TCN  201  than  older  cells;  I
hypothesize this is because young GluN2A transfected cells predominately express
diheteromeric  GluN2A  NMDARs  but  older  cells  express  both  diheteromeric
GluN2A and triheteromeric GluN2A-GluN2B NMDARs. 
The developmental upregulation of GluN2A detected in chapter 4 can theoretically
occur  via  transcriptional,  translational  and  post-translational  mechanisms  as
discussed in section 1.2. Therefore, in chapter 5, I question whether selective post-
translational mechanisms at the GluN2B CTD is necessary for the developmental
upregulation of GluN2A. To achieve this, cortical cultures where the GluN2A CTD
has genetically been replaced with the GluN2B CTD (named GluN2A2B(CTR)) were
utilized. This has the functional consequence that both GluN2A and GluN2B will be
regulated in the same manner via the CTD. There is  no significant difference in
whole-cell NMDA currents, ifenprodil sensitivity and the proportion of synaptic and
extrasynaptic  NMDARs  when  comparing  GluN2A(2BCTD)  and  wild  type  cultures.
Furthermore,  GluN2A(2BCTD)  cultures  showed  enhanced  NMDA-dependent
excitotoxicity but no impairment in the expression of several immediate early genes
triggered  by  synaptic  activity.  Altogether,  it  can  be  concluded  that  when  both
GluN2A and GluN2B are subjected to the same post-translational modifications at
the CTD, the developmental upregulation of GluN2A still occurs. Consequently, this





2.1 Neuron culture and genetic manipulations
2.1.1 Primary culture of cortical neurons derived from rodents
Tissue culture grade 24-well plates (Grenier Bio-One) were incubated for at least
two  hours  at  37°C  in  poly-D-lysine  (molecular  weight  30,000  –  70,000)  and
Laminin  (Sigma).   Sterile-glass  coverslips  (VWR)  were  placed  in  a  well  if  the
neurons were to be used for electrophysiology experiments. Cortical neurons were
cultured from embryonic day 21 Sprague Dawley rat pups or from embryonic day
17.5 C57BL/6 mouse pups. Mouse pups were decapitated immediately whereas rat
pups  were  anaesthetized  with  anintraperitoneal  injection  of  pentobarbital  (Ceva
Sante Animale, La Ballastiere, France) prior to decapitation; both procedures were
in accordance with schedule 1 of the home office guidelines for humane killing of
animals.  The required number  of  cortices  was promptly removed in  dissociation
medium at room temperature (81.8mM Na2SO4, 30 mM K2SO4, 5.84 mM MgCl2,
0.252  mM  CaCl2,  1  mM  HEPES,  20  mM  D-glucose,  0.001%  Phenol  Red)
supplemented with 1mM kynurenic acid to block NMDAR mediated excitotoxicity.
The  cortices  were  then  incubated  at  37oC  with  2ml  of  dissociation  media
supplemented  with  papain  (10  enzymatic  units/ml)  (Worthington  Biochemical
Corporation)  for 20 minutes and then this process was repeated.  From this point
forward, all fresh media used were pre-warmed at 37oC. The tissue was then washed
twice  with  dissociation  media  followed  by  2  washes  with  growth  medium
(Neurobasal-A medium supplemented with  1% Rat Serum (Harlan SeraLab), B-27
Supplement , 1 mM glutamine and an antibiotic-antimycotic agent (all Invitrogen).
After washing, corticies were homogenized by rapid suction/expulsion using a 2 ml
disposable plastic pipette in 10 ml of growth medium. This cell suspension was then
diluted using Opti-MEM (Invitrogen) supplemented with Glucose (20 mM) and an
an antibiotic-antimycotic agent, to obtain a concentration of one cortical hemisphere
per  14  ml  cell  suspension  for  rat  and  one  cortical  hemisphere  per  7  ml  cell
suspension for mouse.   This cell  suspension was then plated at  0.5ml/well  (area
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1.9cm2) and the plates were then placed in a humidified 5% CO2 atmosphere at
37°C for 2 hours. After this plating step, the media was replaced with 1 ml of growth
medium (described above). On DIV 4,   1 ml of growth medium containing 9.6 μM
cytosine β-Darabinofuranoside hydrochloride (AraC) was added to each well to prevent
proliferation of glial cells. To maintain cells, 1ml of conditioned media was removed
and replaced with the growth medium described above except the rat serum was absent
and 10 mM glucose was supplemented; this maintenance typically occurred on DIV 9,
12 and 14. 
2.1.2 Maintenance and preparation GluN2A2B(CTR) cultures 
The  GluN2A2B(CTR) line  was  generated  by the  Komiyama lab  (The  University  of
Edinburgh) and details of the creation can be found in  (Ryan et al. 2013). For the
studies  in  this  thesis,  all  animals  were  maintained  in  house  at  the  Centre  for
Integrative Physiology. The Ensembl transcripts ID for Grin2b described here is:
ENSMUST00000053880  and  for  Grin2a is:  ENSMUST00000032331.  For
genotyping of the GluN2A2B(CTR) colony utilizing PCR, the following strategy was
implemented as illustrated in figure 2.1. 
To determine the genotype of mice in the colony, the DNA was extracted from ear
notches by boiling at 100oC in  50 mM NaOH (600 µl) for 10 minutes. This was
followed by the addition of 60 µl of 1M tris-HCl and protein contamination was
minimized by centrifuging at maximum speed for 10 minutes. Each PCR reaction
contained:  1 µl of  DNA sample, 0.5 µL of 4 primers listed in  figure 2C,  12 µl
HotStarTaq Master Mix  (Qiagen) and 10 µl DNAase-free H2O. The PCR conditions
were as follows: 5 minutes at 95°C followed by 34 cycles of 94°C for 30 seconds,
55°C for 1 minute and 72°C for 1 minute, followed by an extension step at 72°C for
10 minutes. The PCR products were run on 1.5% agarose gel and visualized using
SYBR Safe ( Life Technologies)  as a DNA stain. 
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Figure 2.1: Genotyping strategy to detect GluN2A2B(CTR) region. (A) Primer set 1 and 2 were 
designed to amplify the Grin2b exon coding for the Glun2B CTR inserted into the Grin2a gene. 
Primer set 3 and 4 were designed to amplify the beginning  of the exon coding for the GluN2A CTR 
and the preceding intronic sequence. (B) The nucleotide sequence of the primer stated in (A). (C) 
PCR products utilizing mouse genomic DNA from a heterozygous/GluN2A+/2B(CTR ) (left), complete 
knock-in of GluN2B CTR into GluN2A subunit/GluN2A2B(CTR) (middle), and a WT/GluN2A+/+. 
To obtain sister GluN2A+/+  and GluN2A2B(CTR) neuronal cultures, male and female
heterozygous  GluN2A+/2B(CTR) mice  were  mated,  and  the  cortices  from individual
pups were cultured  as  described in  section 2.1.1 above.  Initially,  the  pups were
genotyped  using  DNA extracted  from the  tails   in  the  same manner  as  the  ear
notches.  However,  I  found  by  obtaining  a  cell-pellet  from  0.5ml  of  the  cell
suspension and lysing the cells in the same manner as the ear notches, there was
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culture procedure, this method was subsequently adopted. 
2.1.3 Transfection of cortical neurons 
Neurons were transfected between DIV 5–9 using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s suggested protocol.  Briefly, pCis-GluN2A (0.4 μg)
(Rutter & Stephenson 2000) together with eGFP (0.2 μg) in a volume of 333 μl was
added  per  well  of  a  24-well  plate.  After  5  hours  this  transfection  solution  was
removed and replaced with Neurobasal-A growth medium (2 ml per well). ß-globin
was used as a positive control for the transfection procedure in some instances. 
Transfection efficiency was approximately 5% with >99% of eGFP-expressing cells
being identified as positive for the neuronal nuclear antigen (NeuN), while <1%
were  positive  for  glial  fibrillary  acidic  protein  (GFAP)  (Soriano  et  al.,  2008).
Electrophysiological  recordings  were  made  from  transfected  neurons  48  h  post
transfection; neurons were selected based on having a healthy/non-swollen soma and
expression of eGFP extensively in dendrites. 
2.2 Electrophysiology
2.2.1 External recording solution: artificial cerebrospinal fluid (aCSF).
Experiments were conducted at room temperature (18–21°C) in an ‘external aCSF’
solution containing (in mM): NaCl 150, KCl 2.8, HEPES 10, CaCl2 2, glucose 10,
EDTA 0.01; pH to 7.3 with NaOH 3 (320-330 mOsm). Mg2+ is omitted from this
ACSF to prevent blockade of the NMDAR.  Tetrodotoxin (300 nM) was included to
block action potential-driven excitatory postsynaptic events when whole-cell NMDA
currents were determined. The external solution was applied with a constant gravity
fed-flow, at a rate of 3-5 ml/min, and the outflow was generally positioned ~1 cm
away from the neuron being patched; this permitted a relatively fast rate of solution
exchange as determined by time taken to reach the peak NMDA current (typically
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300 ms- 800ms). 
2.2.2 Recording electrodes and internal solution
Patch  pipettes  were  made  from thick-walled  borosilicate  glass  with  dimensions
1.5mm  O.D.  x  0.86  I.D  containing  a  filament  (Harvard  Apparatus).  Glass  was
mounted onto a Flaming Brown Micorpipette Puller (Model 97; Sutter instruments)
and pulled into a patch electrode to have a final resistance between 4-8MΩ. The
recording electrodes were filled with a filtered  ‘internal’ solution that contained (in
mM) potassium gluconate 141, NaCl 2.5, HEPES 10, EGTA 11; pH 7.3 with KOH. 
2.2.3 Recording Whole cell NMDA currents in voltage clamp
Whole-cell  NMDA-evoked  currents  in  cultured  neurons  were  recorded  using  an
Axopatch  200B  amplifier  (Molecular  Devices).  Cortical  neurons  were  voltage
clamped between -60 mV and -70mV and NMDA currents  were evoked by the
application  of  the  co-agonists  NMDA +  glycine  in  the  aCSF  described  above.
Specific details of clamp voltages and concentrations of NMDA/glycine utilized are
given in figure legends in subsequent chapters. Access resistances were monitored
and, recordings where this changed by >20% or exceeded 30 ΩM were discarded.
Holding currents were typically less than -100 pA. Currents were filtered at 2 kHz
and digitized at 5 kHz via a BNC-2090A/PCI-6251 DAQ board interface (National
Instruments, Austin, TX) and analysed using WinEDR software (Dr John Dempster,
University of Strathclyde, Glasgow, UK) for further off-line analysis.
2.2.4 Promoting synaptic activity in current clamp
Whole  cell  patch  clamp recordings  were  attained in  the  same manner  discussed
above.  However,  1  mM MgCl2 was  included  in  the  aCSF to  prevent  NMDAR-
dependent  epileptiform activity and 50 µM bicuculline supplemented to  promote
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synaptic activity via the inhibition of GABARs. Neurons were allowed to fire action
potentials  at  their  resting  membrane  potential.  The  liquid  junction  potential  was
estimated to be 11 mV using the junction potential calculator (pCLAMP 9) therefore
a criteria was set prior to experimentation that the resting membrane potential must
be < -50 mV. 
2.2.5 Two electrode voltage-clamp of Xenopus oocytes expressing NMDARs
Experiments performed by Griffiths N.H., Butters P.A., Edman, S., Samadi, M &
Macdonald L.J. 
Briefly,  two-electrode  voltage-clamp  (TEVC)  recordings  were  made  using  a
GeneClamp 500 amplifier (Molecular Devices, Sunnyvale, CA) at room temperature
(18–21  °C)  from  oocytes  placed  in  a  bath  that  was  perfused  with  a  solution
comprising (in mM): NaCl 115, KCl 2.5, HEPES 10, BaCl2 1.8, EDTA 0.01; pH 7.4
with  NaOH.   Current  and  voltage  electrodes  were  made  from  thin-walled
borosilicate  glass  (GC150TF-7.5,  Harvard Apparatus,  Kent,  UK) using a PP-830
electrode puller (Narishige Instruments, Tokyo, Japan) and when filled with 0.3 M
KCl  possessed  resistances  of  between  1  and  2  MΩ.  TEVC  recordings  were
performed at −30 or −40 mV. Currents were filtered at 10 Hz and digitized online at
100 Hz, via a Digidata 1200 A/D interface (Molecular Devices, Union City, CA,
USA),  using  WinEDR  3.1.9  software  (Strathclyde  Electrophysiology  Software,
Strathclyde University, UK). 
2.3 Determining NMDAR-dependent excitotoxicity
To elicit an excitotoxic insult, neurons were first placed overnight into a minimal
defined medium (Papadia et al., 2005) containing 10% MEM (Invitrogen), 90% Salt-
Glucose-Glycine  (SGG) medium; SGG: 114 mM NaCl,  0.219% NaHCO3,  5.292
mM KCl,  1 mM MgCl2,  2 mM CaCl2,  10 mM HEPES, 1 mM Glycine,  30 mM
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Glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolarity 325 mosm/l.  To
induce neuronal death, neurons were exposed to NMDA at various concentrations
and times; this is further stipulated in subsequent figure legends where necessary.
To terminate NMDAR activation, 10 µM MK-801 was added at the desired time
point. Exposure to excitotoxic concentrations of NMDA leads to neurons displaying
swollen cell bodies and pyknotic nuclei with small irregular chromatin inclusions.
Such characteristics are indicative of necrotic, as opposed to apoptotic, cell death.
The  cells  were  fixed  24  hours  after  exposure  to  NMDA  and  the  cell  death
determined by calculating the ratio of DAPI (Vectorlabs) stained pyknotic nuclei as
a  percentage  of  the  total  nuclei.  Images  were  taken  using  a  Leica  AF6000  LX
imaging system, with a DFC350 FX digital camera.
2.4 Determining changes in mRNA expression upon synaptic activity
2.4.1 Stimulation and harvesting of RNA
DIV 16 neurons were placed overnight in the SGG/10 % MEM media described
above. On DIV 17, the neurons were stimulated with 50 µM bicuculline to promote
synaptic activity for fours hours. After the stimulation, Total RNA was isolated using
High Pure RNA Isolation Kit (Roche) including a DNase-treatment step to degrade
genomic DNA. The total RNA was eluted in 50 μl of RNase-free water and stored at
-80oC. 
2.4.2 RT-PCR and Quantitative-PCR
cDNA was synthesized from 1-5 μg of total RNA using Transcriptor First Strand
cDNA Synthesis Kit (Roche). The reverse transcription reaction was carried out by
mixing 7 μl of RNA with 13 μl reverse transcriptase (RT) mix containing Anchored-
oligo(dT) primer: random hexamer primer 1:2 (total 3 μl), 4 μl transcriptor reverse
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transcriptase reaction buffer (5X), 0.5 μl protector RNase inhibitor (40 U/μl), 2 μl
deoxynucleotide Mix (1mM each:dATP,dGTP,dTTP, and dCTP), 0.5 μl transcriptor
reverse transcriptase (20 U/μl) and 3 μl nuclease free water. At least one sample was
prepared  with the  omission  of  reverse  transcriptase  as  a  positive  control.  cDNA
synthesis  reactions  were  all  carried  out  at  25°C  for  10  minutes  (for  primer
annealing), 30 minutes at 55°C (for the reverse-transcription reaction), 5 minutes at
85°C (for enzyme inactivation) and then finally held at 4°C.
This cDNA was then diluted to 6 ng/μl and qPCR was performed in a Mx3000P
qPCR  System  (Stratagene)  using  FastStart  Universal  SYBR  Green  Master  Mix
(Roche). A qPCR reaction mix, containing 1 μl template cDNA, 7.5 μl SYBR Green
master mix ,0.6 μl forward and reverse primers at a final concentration of 200 nM
and 5.3 μl nuclease free water was prepared on ice. 15 µl of this reaction mix was
pipetted into each well in technical replicates alongside a templatee-free control and
a RT-PCR reaction prepared with no reverse transcriptase. The cycling program was
10 min  at  95  °C;  40  cycles  of30 s  at  95  °C,  40  s  at  60  °C with  detection  of
fluorescence and 30 s at 72 °C; followed by one cycle of 1 min at 95 °C, 30 s at 55
°C  ramping  up  to  95  °C  over  30  s  with  continuous  fluorescence  detection.
Expression of the gene interest was calculated using the efficiency corrected 2 (-ΔΔCt)
method (Livak & Schmittgen 2001), normalising to the housekeeping gene GAPDH.
The sequence and efficiencies of primers used are shown below. 
Gene Efficiency
(%)
Forward Primer (5' to 3') Reverse Primer (5' to 3')
GAPDH 104 GGGTGTGAACCACGAGAAT  CCTTCCACAATGCCAAAGTT
BDNF 101 AAAGTCCCGGTATCCAAAGG CTTATGAATCGCCAGCCAAT
FOSB 99 AGGGAGCTGACAGATCGACTT CTTCGTAGGGGATCTTGCAG
NPAS4 96 AGGGTTTGCTGATGAGTTGC CCCCTCCACTTCCATCTTC
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2.5 Materials
The  following  drugs  were  purchased  from  Tocris  (Birstol,  UK):(+)/-MK-801
Maleate, ifenprodil hemitartrate, NMDA, tetrodotoxin citrate, bicuculline, and TCN
201. TCN 213 was first initially purchased from Enamine (Kiev, Ukraine) and then
subsequently from Tocris. All other components of aCSF and SGG were purchased
from Sigma. 
2.6 Statistics and curve fitting 
All results are presented as mean ± standard error of the mean. Statistical testing
largely involved a 2-tailed student t-test.(Excel, Microsoft). 
To determine the dose-response relationship in an excitotoxicity experiment, the 
dose-response equation below was fitted using OriginLab for graphing and graphPad
Prism for statistics: 
Where:
• A1 =  initial Y value
• A2 = final Y value 
•  ƿ= hill slope
• x0 = EC50
Todetermine  whether  the  dose-response  relationships  were  significantly  different
between groups,  the  extra  sum of  squares  F-test  was utilized.  This  fits  a  global
model and subsequently calculates the probability of both groups having the same




Recovery of NMDAR currents from MK-
801 blockade is accelerated by Mg2+ and the




Selective  activation  of  synNMDARs  by  enhancing  phasic  synaptic  activity  is
neuroprotective whilst tonic activation of both synNMDARs and exNMDARs leads
to excitotoxicity  (Giles E. Hardingham & Bading 2010). As discussed in  1.4.1, by
promoting synaptic activity in the presence of the use-dependent antagonist MK-
801, it is possible to selectively block synNMDARs and subsequently selectively
activate  exNMDARs  by  exogenous  application  of  NMDAR  agonists.  Such
approaches  revealed  that  selective  activation  of  exNMDARs  is  sufficient  to
depolarize mitochondria, a critical step in excitotoxicity (Hardingham et al. 2002).
This, in part, led to the hypothesis that exNMDARs may preferentially couple to
excitotoxicity. 
Recently,  rather  than  measuring  indirect  measurements  of  excitotoxicity  such  as
mitochondrial depolarization depolarization evoked by exNMDARs,  studies have
attempted  to  induce  neuronal  death  itself  by  selectively  activating  exNMDARs
utilizing MK-801 blockade of synNMDARs (Wroge et al. 2012; Zhou et al. 2013) as
elaborated in  section 1.4.1.2.  As the attempted selective activation of exNMDARs
failed  to  induce  neuronal  death,  both  studies  concluded  synNMDARs  must  be
critical in mediating excitotoxicity.  As the hypothesis that synNMDARs may be the
primary mediator of excitotoxicity is in stark contrast to a wide body of literature
(Hardingham & Bading 2010), I decided to investigate this hypothesis further. 
It has largely been assumed that MK-801 is an “irreversible” antagonist  (reviewed
by Parsons & Raymond 2014).  Indeed, this must be true for the findings of Wroge
et al. and Zhou et al. to be valid.   Neuroprotection from blocking synNMDARs with
MK-801 was observed after 2.5 hours of 50 µM glutamate (Wroge et al) and after 24
hours  of  a  100  µM  NMDA  exposure  (Zhou  et  al.).  However,  the  original
characterization demonstrated the off-rate of MK-801 was use dependent with a time
constant  for  recovery  of  92±106min  (mean±SD)  (Huettner  &  Bean  1988).
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Importantly, the time constant calculated was determined using 30 µM NMDA in
steady state conditions; if a higher concentration of NMDA was used then the open
probability of the NMDAR would increase ultimately resulting in a decrease in the
time constant. Furthermore, the large standard deviation suggests some cells had a
faster recovery than others perhaps because of insufficient washout. Nevertheless, it
is evident from this very early study that MK-801 is not an irreversible antagonist
under constant agonist exposure. 
Furthermore, Mg2+  can competitively inhibit MK-801 binding (Reynolds & Miller
1988; Huettner & Bean 1988) which is not surprising as they share an overlapping
binding site (Kashiwagi 2002). However, the effect of Mg2+ on MK-801 dissociation
had yet to be established. Therefore, I wished to revisit the issue of MK-801 stability
both in the presence and absence of physiological concentrations of Mg2+ with a
focus  on determining the  suitability of  MK-801 to permit  selective exNMDARs
activation via the blockade of synNMDARs with MK-801. 
I  found  that  high  concentrations  of  agonist  (100  µM  NMDA)  could  induce
significant recovery from MK-801 blockade in 10 minutes; this recovery could be
accelerated by co-applying either 1 mM MgCl2  or 10 µM memantine which also
shares an overlapping binding site with both MK-801 and Mg2+. Furthermore, a non-
toxic lower agonist dose (15 µM NMDA) could induce significant recovery after 30
minutes in the presence of 1 mM MgCl2. I hypothesized that if low doses of NMDA
could  induce  recovery,  then  higher  doses  should  result  in  excitotoxicity.
Surprisingly, unlike constant perfusion, I found it is very difficult to remove all MK-
801 in a static cell culture well which may explain the lack of unblocking observed
by Wroge et al. and Zhou et al. However if washout was thoroughly executed then
2.5 hours of high agonist exposure is sufficient to induce widespread excitotoxicity
post blocking all NMDARs with MK-801. 
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Altogether, it can be concluded that in the presence of both agonist exposure and
physiologically  relevant  concentrations  of  Mg2+,  MK-801  is  not  an  irreversible
antagonist.  This  confines  a  temporal  limit  in  which  selective  activation  of




3.2.1 In the absence of TTX, Mg2+-free conditions result in glutamate spillover
to extrasynaptic sites
Previously  it  has  been  shown that  synNMDARs can  be  successfully  selectively
blocked with MK-801 in Mg2+-free conditions but TTX was co-applied in order to
silence  network  activity;  spontaneous  quantal  release  of  glutamate  provides
sufficient NMDAR channel opening for MK-801 to block  (Puddifoot et al. 2012;
Nakayama et al. 2005). Silencing of network activity is critical as lowering Mg2+ is
well known to induce epileptiform activity due to the relief of the voltage block of
NMDAR by Mg2+   (Stanton et al. 1987). However,  Wroge et al. 2012 attempted to
isolate synNMDARs in Mg2+-free conditions supplemented with 50 µM bicuculline
but  lacking  TTX  (albeit  in  lower  1  mM  CaCl2 conditions).  In  our  hands,  this
protocol blocked 98.1±1.1% of all NMDARs as determined by comparing the initial
whole-cell  NMDA current  to that  of sister  control  cells  as shown in  Figure 1C
(examples  traces  in  Figure  1A and  1B).  Figure  1D illustrates  the  burst  firing
induced by bicuculline and the epileptic activity than ensues if switched to Mg2+-
free ACSF. It is therefore reasonable to conclude that epileptiform activity induced
by Mg2+-free conditions results in glutamate spillover to extrasynaptic sites which
can be blocked by MK-801. It is possible that the lower density culture used by
Wroge et al. may not have such drastic epileptiform activity. 
Nevertheless, the incremental recovery from MK-801 blockade upon each NMDA
application illustrated in Figure 1B was of great interest. This observation lead to a
review of the literature and the subsequent hypothesis that other channel blockers
such as Mg2+ and memantine may promote the recovery from MK-801 blockade. 
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Figure 1:epileptiform activity leads to to glutamate spillover. (A) Untreated cells
exposed to NMDA (100 µM)  reach a steady state current after  2-3 applications
when voltage-clamped at -60mV. (B) A cell exposed to ACSF with 10 µM MK-801
and  50  µM bicuculline  but  lacking  TTX and Mg2+ for  10  mins  has  drastically
reduced NMDA currents compared to 1A. Note the incremental increase in NMDA
current due to the use-dependent recovery of MK-801 blockade.  (C)  Summary of
data:  98.1±1.1% reduction in current density of cells treated with MK-801 in the
above condition. (D) In current clamp, 50 µM bicuculline induces bursts of synaptic
activity. If switched to Mg2+-free ACSF, the cell undergoes epileptiform activity. 
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Cell exposed to ACSF with MK-801 
and bicuculline but lacking TTX and 






3.2.2 Antagonism of NMDARs by Mg2+ and memantine 
Prior to testing the hypothesis that open channel blockers may promote the recovery
of  MK-801  blockade,  I  wanted  to  confirm  their  antagonism  in  our  hands  is
consistent with the current literature. Indeed, when a cortical neuron was voltage-
clamped at -60mV, the time constant for 1mM MgCl2 block under agonist exposure
was  <  200 ms  and the  time  constant  for  the  recovery from this  blockade  <  1s
(Figure 2A). Furthermore, Mg2+ dissociates from the channel pore in the absence of
agonist. 
On the other hand, 10 µM memantine has a slower on-rate and off-rate than Mg2+
(Figure  2B) consistent  with  the  literature  (Chen  & Lipton  1997;  Parsons  et  al.
1995). Nevertheless, unlike MK-801 but similar to Mg2+, memantine can leave the
channel pore in the absence of agonist (Figure 2C). Of note is the ~90% block by
memantine; this is evidence that under high tonic agonist exposure where there is no
difference in concentrations at synaptic or extrasynaptic sites, memantine does not
discriminate between synaptic and extrasynaptic NMDARs. 
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Figure 2: Antagonism of NMDARs by Mg2+ and memantine. 
(A) When voltage-clamped at -60mV, 1 mM MgCl2 blocks the inward current 
induced by 100 µM NMDA by ~90%. This blockade can quickly be reversed in the 
presence and absence of NMDA. (B) 10 µM memantine also reduces the inward 
current induced by 100 µM NMDA by ~90% but both the on-rate and off-rate is 
considerably slower than Mg2+. (C) The recovery from 10 µM memantine blockade 





3.2.3 Mg2+ and memantine accelerate the recovery of MK-801 blockade in the
presence of agonist
To determine if Mg2+ and memantine could accelerate MK-801 leaving the channel
pore,  I  first  had to establish a  reproducible  assay.  Firstly,  I  recorded the inward
current induced by 100 µM NMDA with the cortical neurons voltage-clamped at
-60mV. Subsequently, I could block all NMDARs by co-applying 100 µM NMDA
and 10 µM MK-801. From here, I could perfuse on varying solutions and determine
the  recovery  of  MK-801  blockade  assayed  by  repeating  the  100  µM  NMDA
exposure.
As illustrated in Figure 3A, ACSF lacking MgCl2 induces very little recovery from
the MK-801 blockade but supplementing the ACSF with 100 µM NMDA promotes
a significant recovery from the blockade; this is consistent with recovery of MK-801
blockade being use-dependent  (Huettner & Bean 1988). Repeating the experiment
with ACSF containing 1 mM MgCl2 but with no agonist also provided very little
recovery (Figure 3B) confirming that Mg2+ alone does not promote MK-801 leaving
the  channel  pore  which  is  consistent  with  previous  Ca2+ imaging  experiments
(Yuzaki  et  al.  1990).  However,  when  ACSF  containing  1  mM  MgCl2  was
supplemented with 100 µM NMDA there was more than twice the recovery from the
MK-801  blockade  than  NMDA alone;  NMDA alone  provides  ~18%  recovery
whereas 1mM MgCl2 + NMDA provides ~50% recovery. Thus, a combination of the
channel  in  an  open  activated  state,  together  with  Mg2+,  promotes  recovery  of
NMDAR currents from MK-801 blockade.
Next I turned my attention to determine if memantine could also promote MK-801
leaving the channel pore. As illustrated in Figure 2, memantine has slower off-rate
kinetics  than  Mg2+ so  I  had  to  modify  the  protocol.  Here,  during  the  MK-801
unblocking phase,  I perfused 10 µM memantine + 100 µM NMDA for 9 minutes
followed by 1 minute of 100 µM NMDA alone to permit the washout of memantine.
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Figure 3: Mg2+ and memantine accelerate the recovery of MK-801 blockade in the presence of
agonist. Cells voltage-clamped at -60mV,   NMDA used at 100 µM, *p < 0.05, Student unpaired t-
test and  scale bar = 5s (x-axis), 200 pA (y-axis) throughout all. 
(A)  whole-cell NMDA currents were recorded followed by blocking all NMDARs by co-applying
NMDA and 10 µM MK-801 (NMDA + MK). Neurons were then continuously perfused for 10 min in
ACSF±NMDA (zero Mg2+), after which whole-cell currents were once again recorded and expressed
as a % of the original current.  (n =8 Con, n =9 NMDA) (B) Same protocol as A except during 10 min
recovery period, ACSF contains 1mM MgCl2..  Dotted line shows the NMDA-induced unblocking
level in the absence of Mg2+. (n=7 Con, n = 8 NMDA). (C)  Same protocol as  (A)  except 10 min
recovery with NMDA had first 9 mins supplemented with 10 µM memantine (Mem) followed by 1





As with Mg2+, memantine also significantly increases the recovery from MK-801
blockade.
Therefore, I propose a model whereby MK-801 cannot leave the channel pore unless
the NMDAR is in the open state induced by agonist binding. Once in the open state,
there is a finite chance MK-801 will rebind rather than leave the pore entirely;  Mg2+
and memantine can promote MK-801 leaving the channel pore by interfering with
MK-801 rebinding to the channel pore. 
The effect of Mg2+ promoting MK-801 leaving the channel pore can be visualized in
real time by studying the effect of repeated applications of NMDA. In figure 3A I
recapitulate the finding that Mg2+ alone does not promote the recovery from MK-801
blockade. In figure 3B, post MK-801 blockade,  9 x 10s pulses of 100 µM NMDA
in ACSF lacking Mg2+ induces an incremental increase in recovery from MK-801
blockade. However, when the 9 x 10s pulses of 100 µM NMDA is repeated in ACSF
containing 1 mM MgCl2 there is no longer a visual incremental increase in recovery.
As the neurons are voltage-clamped at -60mV, this is to be anticipated because as
MK-801 leaves the channel, it is substituted by Mg2+ binding to the channel pore and
blocking the NMDAR. Only when the neuron is switched to ACSF lacking Mg2+ and
100  µM NMDA re-applied  is  the  extent  of  MK-801  unblocking  revealed  ;  co-
applying  NMDA +  Mg2+  induces  nearly  twice  (29%)  the  recovery  of  MK-801
blockade compared to NMDA alone (16%). This supports the evidence that Mg2+
promotes MK-801 leaving the channel pore. 
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Figure 4: Illustration of the influence of repeated applications of NMDA  Mg2+
on recovery from MK-801 blockade. Cells voltage-clamped at -60 mV, NMDA
(NM) used at 100 µM, MK-801 (MK) used at 10 µM and  scale bar = 25s(x-axis),
400 pA (y-axis) throughout all. AC = ACSF
(A) Steady state  NMDA current  was were  determined and all  NMDA receptors
subsequently blocked by co-applying NMDA + MK-801. Perfusion of ACSF+ 1mM
MgCl2 provides little recovery from MK-801 blockade. 
(B) Same protocol as A except post blockade by MK-801, 9 x 10s pulses of NMDA
in ACSF lacking Mg2+ results in an incremental recovery of MK-801 blockade.
(C) Same protocol as B except 1 mM MgCl2 was co-applied with the 9 x 10s pulses
of  NMDA.  Under  these  conditions,  there  is  no  incremental  increase  in  NMDA
currents with each application of NMDA.  This is because as MK-801 leaves the
channel,  it  is  substituted  by Mg2+  binding  to  the  channel  pore  and blocking the
NMDAR.  When the neuron is  switched to ACSF lacking Mg2+  and NMDA re-
applied the extent of MK-801 unblocking revealed (29%). 
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3.2.4 Recovery of MK-801 blockade in un-clamped neurons
As the overall aim of this chapter is to determine the suitability of MK-801 to stably
block  synNMDARs  under  physiological  conditions,  it  is  important  to  identify
caveats in the previous experiments. During the first 10 minutes in the whole-cell
configuration of a patch-clamp recording there is a dialysis of intracellular factors,
which although unlikely, may effect MK-801 leaving the channel pore. Furthermore,
voltage-clamping  a  neuron  by  definition  is  not  physiological.  Lastly,  the  above
experiments were conducted at room temperature; MK-801 recovery may be greater
at the more physiologically relevant 37oC. 
To  address  the  above,  I  wished  to  determine  un-clamped  MK-801  recovery  in
minimal media containing physiologically relevant concentrations of MgCl2 (1mM)
at 37oC. To achieve this, all NMDARs were pre-blocked by co-applying 100 µM
NMDA + 10 µM MK-801 for 3 mins in the cell culture well. This was followed by
thoroughly  washing  and  removing  the  MK-801  which  involved  sequentially
transferring the coverslip along a row of 5 wells each containing fresh media as
illustrated in  Figure 5A.  At  this  stage,  if  the neurons were exposed to  100 µM
NMDA  in  the  voltage-clamp  configuration,  virtually  no  NMDA  current  was
obtained confirming all the NMDARs were blocked (Figure 5 B + C). 
From here, the neurons were placed in media containing 15 µM NMDA and 1 mM
MgCl2 for either 30 mins or 150 mins (as were untreated control cells). We chose the
low 15 µM NMDA dose as it is non-excitotoxic to young rat cortical cultures and I
wanted  to  ensure that  the  neurons  would  not  die  if  MK-801 dissociated  from a
substantial proportion of NMDARs. After 30 mins exposure to 15 µM NMDA, the
cells  that  were  pre-blocked  with  MK-801  had  currents  that  were  ~50% of  that
obtained  in  sister  control  cells  (Figure  5A)  and  after  150  mins,  there  was  no
significant difference between cells that were pre-blocked with MK-801 and control
cells  (Figure  5B).  These  experiments  confirm  that  even  low  doses  of  NMDA,
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combined with physiologically relevant media containing 1 mM MgCl2, can induce
substantial recovery from MK-801 blockade within 30 minutes. 
75
Figure 5: Recovery of MK-801 blockade in un-clamped neurons. 
 *p < 0.05, Student unpaired t-test (n = 7 in all conditions)
(A) Illustration to demonstrate the blocking of all NMDARs in the culture well (pre-block),
the subsequent washing steps to remove all MK-801 and finally, the exposure of the neurons
to a non-toxic dose (15 µM) of NMDA for either 30 mins or 150 mins. (B) 15 µM NMDA
for 30 mins significantly increases recovery of MK-801 blockade. After cells that were pre-
blocked with MK-801 and subsequently exposed to 15 µM NMDA, their whole-cell NMDA
currents were determined by exposure to 100 µM NMDA as prior. Pre-blocked whole  cell
currents were normalized to whole-cell NMDA currents of sister control cells. A significant
recovery of ~50% was determined. *p < 0.05, Student unpaired t-test. 
(C)  As  (B)  except 15 µM NMDA exposure was for 150 mins. There was no significant





3.2.5 Agonist-induced recovery from MK-801 blockade can lead to excitotoxic
cell death
If 15 µM NMDA can result in ~50% of MK-801 dissociating from the NMDARs
within 30 mins, I hypothesized that higher concentration of agonist would provide a
faster rate of unblocking and ultimately induce excitotoxic signalling. Furthermore,
at this stage, I questioned why Wroge et al. 2012 failed to see very little recovery
from MK-801 blockade under hypoxic conditions of 150 mins;  the data presented
so far in this chapter would predict a substantial MK-801 unblocking under hypoxic
conditions.
To this  end,  I  questioned whether  the  multi-well  washout  protocol  illustrated  in
figure  5A was  essential  to  remove  all  the  MK-801.  I  specifically  designed  the
protocol to be robust in the removal of MK-801 as it was appreciated that MK-801
is largely used in excess ; MK-801 has an IC50 of ~30-50 nM and it is routinely used
around 200 times this at 10 µM. 
To test this hypothesis, I first blocked all NMDARs by co-applying 100 µM NMDA
+ 10 µM MK-801 for 10 minutes. One subset of neurons were washed 5 times in a
single well with fresh media and then exposed 100 µM NMDA for 150 mins whilst
another  group had the multi-well  wash illustrated in  Figure 4A followed by the
same NMDA exposure as the neurons that  underwent the single well  wash. The
toxicity was terminated by the addition of 10 µM MK-801, the cells were fixed 24
hours later and cell death determined.  Only the neurons that received the multi-well
had widespread NMDA excitotoxicity (Figure 6A). Two important conclusions were
derived from these data. Firstly, even when all NMDARs are blocked, 150 mins of
high agonist exposure induces relief of the MK-801 blockade sufficient enough to
induce excitotoxicity. Secondly, contaminating MK-801 from incomplete washout is
likely to lead to erroneous conclusions. 
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If it genuinely is difficult to remove all 10 µM of MK-801 by washing a single well,
I  reasoned  that  lowering  MK-801  concentration  would  alleviate  this  problem.
However, the concentration would still need to block the majority of NMDARs in
addition to blocking NMDA induced excitotoxicity. I determined that lowering MK-
801 20-fold to 500 nM and co-applying with 100 µM NMDA for 10 minutes in cell
culture media, reduced the whole-cell NMDA currents by 93% when comparing to
the  whole-cell  NMDA currents  of  sister  control  cells  (Figure  6B).  Therefore,  I
concluded 500 nM MK-801 would be suitable to block excitotoxic signalling. 
Next, I demonstrated that 100 µM NMDA for either 30 mins or 150 mins causes
greater than 80% of the cortical neurons to die (figure 6C); the remaining cells are
likely to be non-neuronal cells such as astrocytes.  500 nM MK-801 co-applied with
100  µM  NMDA for  150  mins  blocks  this  excitotoxicity  as  predicted.  I  then
demonstrated that pre-blocking the NMDARs with 100 µM NMDA and 500 nM for
10 mins and subsequently then washing the single well 5 times with fresh media
does not produce excitotoxicity. If after the pre-block and wash, 100 µM NMDA is
applied  for  30  mins  then  little  excitotoxicity  is  observed  but  if  this  period  is
extended to 150 mins then again, I recapitulate greater than 80% of neurons had died
24 hours later. 
From this, I conclude that lowering MK-801 20-fold now permits MK-801 to be
washed out in a single well. After 30 mins of NMDA exposure post pre-block, even
though the recovery from MK-801 may well  be complete,  there is  not sufficient
excitotoxic signalling to induce cell death. However, after 150 mins of exposure,
there is now adequate excitotoxic signalling that the excitotoxic insult is similar to
that if the neurons were not pre-blocked with MK-801 at all. It should be stressed
that  just  because  little  excitotoxicity  occurred  at  30  mins  does  not  mean  no
excitotoxic signalling had occurred; the slow incremental increase in Ca2+ influx as
the MK-801 leaves NMDARs is in all likelihood, a temporal pattern of Ca2+ influx
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that will never occur  in vivo. Measuring any changes in cellular signalling during
this period would be difficult to equate to relevant physiology. 
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Figure 6: Agonist-induced recovery from MK-801 blockade can lead to excitotoxic
cell death.  In  A and  C each condition,  n = 3 independent cultures. Each  n was determined by
averaging the cell death in 4 wells or coverslips.  *p < 0.05, Student unpaired t-test 
(A) Neurons were pre-blocked with 10 µM MK-801 and 100 µM NMDA for 10 mins. Afterwards,
one group received a 'one-well'  wash which involved washing the single well 5 times with fresh
media whereas another group received a 'multi-well' wash as illustrated in figure 5A. Afterwards, a
subset of each wash group was exposed to 100 µM NMDA for 150 mins. The NMDA insult was
terminated by applying 10 µM MK-801. Subsequently,   the cells were fixed  24 hours later and cell
death analysed. (B) Exposure to 100 µM NMDA and 500 nM MK-801 for 10 mins reduces whole-
cell NMDA currents evoked by 100 µM NMDA by 93% when compared to sister control cells. n = 5
for both conditions. (C)  Exposure to 100 µM NMDA for either 30 mins or 150 mins causes >80% of
neurons to die. Co-applying 500 nM MK-801 can block excitotoxicity induced by NMDA for 150
mins.  Pre-blocking  neurons  with  100  µM  NMDA  +  500  nM  for  10  mins  does  not  induce
excitotoxicity and neither does subsequently washing the well 5 times with fresh media post pre-
block.  If after the pre-block + wash, 100 µM NMDA is applied for 30 or 150 mins, only at 150 mins
is  neuronal  death  observed.  The  NMDA insult  was  terminated  by  applying  10  µM  MK-801.






It can be concluded from this study that in the presence of both continuous agonist
exposure and physiologically relevant concentrations of Mg2+,  MK-801 is not an
irreversible antagonist. This imposes a temporal limit in which selective activation
of  exNMDARs  can  occur  if  experiments  are  conducted  in  physiological
concentrations of Mg2+. To elaborate, the data presented does negate the selective
block of synNMDARs by MK-801 if the observation of exNMDARs occurs over a
matter of seconds; the wide spread use of MK-801 to determine the proportion of
synaptic vs extrasynaptic NMDARs remains a valuable experimental tool. However,
this  study  clearly  demonstrates  this  approach  is  not  appropriate  to  investigate
specific  cellular  signalling  which  occurs  over  a  matter  of  minutes;  this  includes
investigating downstream signalling of exNMDARs and any potential consequences
such as cell death. 
It could be argued that utilizing Mg2+-free media to reduce MK-801 dissociation at
synNMDARs  is  an  alternate  approach  to  increase  the  time  window  in  which
selective activation of exNMDARs can occur.  However,  in  Mg2+-free media,  the
Ca2+ influx at exNMDARs will be significantly elevated due the Mg2+ block of the
NMDAR being absent. The same line of reasoning can be projected to synNMDARs
that have underwent MK-801 dissociation. Ultimately,  conducting experiments in
Mg2+-free media will result in an undesirable temporal Ca2+ influx, reminiscent of
epileptiform activity  (as  illustrated  in  Figure  1D),  which  would  be  difficult  to
interpret to a pathological condition in vivo. 
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3.2 Do synaptic NMDARs mediate neuronal death?
As  discussed  in  section  1.4,  selective  activation  of  synNMDARs by enhancing
phasic  synaptic  activity  is  neuroprotective  whilst  tonic  activation  of  both
synNMDARs  and  exNMDARs  leads  to  excitotoxicity  (Hardingham  &  Bading
2010). However, this does not prove synNMDARs cannot mediate excitotoxicity as
there is  a temporal  difference between the phasic  and tonic activation.  Selective
block  of  synNMDARs  with  MK-801  showed  that  brief  selective  activation  of
exNMDARs was sufficient to depolarize mitochondria suggesting    exNMDARs
may preferentially couple to excitotoxicity  (Hardingham et al.  2002).  Again,  this
does not rule out completely that synNMDARs do not mediate excitotoxicity. 
Recently, the MK-801 approach has been extended for a time period which would
induce  excitotoxicity.  This  has  lead  to  the  hypothesis  that  synNMDARs  alone
mediate excitotoxicity  (Wroge et  al.  2012) in addition to both synNMDARs and
exNMDARs mediating excitotoxicity (Zhou et al. 2013). Unfortunately, data in both
studies are incompatible with this study. Wroge. et al show that post blocking all
NMDARs with MK-801, very little recovery of NMDA currents is observed after
2.5  hours  of  hypoxic  conditions.  Although  it  is  difficult  to  gauge  what
concentrations  of  tonic  glutamate  would  be  released  during  hypoxia,  it  is   high
enough to induce excitotoxicity, and data in Figure 5 show that even low non-toxic
doses of agonist (15 µM NMDA)  for 2.5 hours causes substantial recovery from
MK-801  blockade  of  the  NMDAR.  Control  experiments  from  Zhou  et  al  are
unfortunately even more incompatible. Here, synaptic NMDARs were isolated by
co-applying bicuculline and MK-801 for 2 mins. After attempting to wash out the
MK-801,  100  µM NMDA was  applied  for  24  hours  and  no  excitotoxicity  was
observed. However, the data in  Figure 6 clearly show that when all NMDARs are
blocked,  only 2.5 hours of 100 µM NMDA is sufficient to remove MK-801 block
and induce excitotoxicity. The most rational explanation why this was not observed
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after 24 hours is  that there is  contaminating MK-801 left  post washing the cells
which protects the neurons from excitotoxicity. Therefore, the conclusions from the
above  studies  must  be  validated  by  other  experimental  approaches  that  do  not
implement MK-801 to block synNMDARs. 
It  should be stressed that the technical manner in which these experiments were
conducted is not being questioned. Indeed, I show in Figure 6 that washing the well
5 times to remove MK-801, the standard practice to remove a drug from a well, was
clearly ineffective in removing MK-801. Although,  the data presented here leads to
the  advocation  of  the  'multi-well  wash'  illustrated  in  Figure  5A as  a  control
experiment when attempting to wash out any drug or lowering of the drug to a more
appropriate concentration as illustrated in Figure 6C. 
As discussed in section 1.4.1, memantine is  proposed to block synNMDARs over
exNMDARs under high tonic glutamate (Xia et al. 2010; Okamoto et al. 2009) but
this conclusion is largely erroneous. This conclusion is derived from evidence that
memantine  does  not  block  synNMDARs  under  synaptic  activation  whereas  if
exNMDARs  are  isolated  using  the  MK-801  approach,  memantine  significantly
blocks exNMDARs under high tonic activation. However, as illustrated in Figure 2,
if both synNMDARs and exNMDARs are activated under tonic activation, 10 µM
memantine  blocks  the  current  by  ~90%.   Therefore,  memantine  would  only
preferentially block exNMDARs if synaptic activity was preserved at the synapse
whilst  simultaneously  there  was  high  tonic  glutamate  at  extrasynaptic  sites.  As
studies often do not recapitulate this environment, neuroprotection from memantine
should not be used as indication that only exNMDARs are mediating excitotoxicity. 
Clearly another approach is needed to dissect out spatially distinct populations of
NMDARs. One such approach involves using enzymes which degrade the NMDAR
co-agonists glycine and D-serine. It has been demonstrated that under physiological
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conditions,  degrading  D-serine  effects  the  activation  of  synNMDARs  whereas
degrading glycine effects the activation of exNMDARs (Papouin et al. 2012b). Only
degrading D-serine was neuroprotective against NMDA excitotoxicity in a mature
hippocampal  slice  so  it  was  therefore  concluded  that  synNMDARs  mediate
excitotoxicity. Whereas this may indeed be the case, further control experiments are
needed.  It  is  possible  that  under  pathological  conditions  such as  tonic  glutamate
exposure, the physiological regulation of D-serine at the synapse is lost and it spills
to extrasynaptic sites; this must be proven to not occur before it is concluded that
synNMDARs mediate excitotoxicity. 
Glutamate uncaging has the major advantage of removing the temporal difference in
activation  of  synNMDARs  and  exNMDARs  which  has  been  heavily  discussed.
Glutamate uncaging (1Hz,  60 secs)  at  only 7 dendritic  spines can activate  ERK
sufficiently  to  detect  CREB phosphorylation  of  ser133  (Zhai  et  al.  2013).  This
clearly demonstrates that even small synaptic Ca2+ transients have the potential to be
neuroprotective.  Using  the  same  uncaging  protocol,  it  would  be  interesting  to
determine  the  effects  of  glutamate  uncaging  at  exNMDARs  on  CREB
phosphorylation to determine if an opposing effect was observed. 
Altogether, it can be concluded that it is relatively difficult to selectively activate
exNMDARs and synNMDARs under the same temporal profile. Whereas there is
overwhelming  evidence  the  that  phasic  activation  of  synNMDARs  mediates
neuroprotective signalling, further research will be needed to determine the specific




of the developmental switch
in the subtype of the GluN2
NMDA receptor subunit 
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4.1 Introduction
As a consequence of diheteromeric GluN2A and GluN2B NMDARs having unique
biophysical properties and divergent CTD regions, it has long been proposed that
much  of  the  complex  physiology  mediated  by  NMDARs  arises  from  the  two
diheteromeric  populations  coupling  to  unique  signalling  cascades  (Shipton  &
Paulsen 2014). However, this hypothesis has been challenged in recent years with
evidence  that  a  prominent  triheteromeric  GluN2A-GluN2B  population  exists  in
hippocampal neurons in culture  (Tovar et al. 2013) and in vitro  slices (Gray et al.
2011; Rauner & Kohr 2011). 
Nevertheless,  selective  antagonism  of  diheteromeric  GluN2A  and  Glun2B
containing NMDARs has been utilized extensively to determine subunit-dependent
signalling by the NMDAR. Selective antagonism of GluN2B containing NMDARs
using ifenprodil has successfully been utilized to study the developmental decrease
in the contribution of GluN2B to NMDAR currents (section 1.2), excitotoxicity and
neuronal protection (section 1.4) and finally synaptic plasticity (section 1.5). 
On  the  other  hand,  NVP-AAM077 has  been  used  to  selectively  block  GluN2A
containing NMDARs with variable success.  As discussed further in section 1.3,    it
is now accepted that low concentrations of NVP-AAM077 (30 nM – 50 nM) can be
utilized to selectively antagonise GluN2A NMDAR-mediated EPSCs  (Tovar et al.
2013) and  GluN2A  NMDARs  activated  under  steady-state  agonist  exposure
(Frizelle et al.  2006)  with minimal antagonism at GluN2B NMDARs. However,
studies have implemented higher concentrations (400 nM) of NVP-AAM077 which
antagonizes both GluN2A and GluN2B NMDARs  (see for example  (Liu et  al.
2004;  Liu  et  al.  2007).    Accordingly,  the  use  of  NVP-AAM007  has  led  to
contradictory  hypotheses  regarding  subunit-dependent  signalling  mediated  by
GluN2A and GluN2B. 
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Therefore it was a great interest when two compounds, subsequently named TCN
213  and  TCN  201,   were  identified  by  a  Ca2+ imaging  screen  that  had  the
pharmacological properties of a GluN2A specific antagonist (Bettini et al. 2010).  At
concentrations  at  the  limit  of  their  solubility,  both  TCN  213  and  TCN  201
demonstrate  no  antagonism at  GluN2B NMDARs and their  potency at  GluN2A
NMDARs  is  dependent  on  the  concentration  of  the  co-agonist  glycine/D-serine
present  at  the NMDAR as  determined by fellow colleagues.  The selectivity and
mechanism of action of TCN 201 was further clarified by Hansen et al. (2012). TCN
201  also  shows  no  antagonism at  GluN2C/GluN2D  NMDARs  and  binds  to  an
allosteric site at a dimer interface between the GluN1 and GluN2A agonist binding
domains; here TCN 201 can modulate the agonist affinity of the GluN1 subunit for
glycine/D-serine.
As direct pharmacological monitoring of the developmental upregulation of GluN2A
has been hampered by the poor selectivity of NVP-AAM077, the pharmacological
characterization  of  these  novel  GluN2A-specific  antagonists  provides  a  unique
opportunity  to  determine  the  developmental  upregulation  of  GluN2A  using  a
combined electrophysiological and pharmacological approach. It was hypothesized
that these compounds would have a low potency in immature cultures where a high
proportion  of  NMDARs  are  diheteromeric  Glu2NB  as  determined  by  the  high
ifenprodil sensitivity.  However, it was predicted that upon maturation of cultures
and a subsequent  fall  in  ifenprodil  sensitivity,  this  would be juxtaposed with an
increase in sensitivity to TN 213 and TCN 201. 
Consequently,  data  in  this  chapter  demonstrates  that  young  neurons  are  highly
sensitive to the selective GluN2B antagonist ifenprodil but are insensitive to TCN
201 & TCN 213 at 3 µM glycine. However, in mature neurons and young neurons
overexpressing GluN2A, a reduced sensitivity to ifenprodil and enhanced sensitivity
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to TCN 201 and TCN 213 is observed. When glycine was increased 10-fold to 30
µM,  GluN2A transfected  neurons  show a  stronger  inhibition  by  TCN 201  than
mature cells.  It is proposed that this observation is a result of GluN2A transfected
cells  predominately expressing diheteromeric GluN2A NMDARs whereas mature
cells  express  both  diheteromeric  GluN2A and  triheteromeric  GluN2A-GluN2B
NMDARs. For this hypothesis to be properly assessed, the potency of TCN 201 at
triheteromeric NMDARs must be further clarified. I also discuss the usefulness of
these  compounds  to  antagonize  GluN2A specific  signalling  under  physiological
conditions. 
These results were partly published  (McKay et al. 2012; Edman et al. 2012). 
88
4.2 Results
4.2.1 Non-endogenous pharmacological characterization of TCN 213 and
         TCN 201 utilizing Xenopus oocytes 
All pharmacological characterization of TCN 201 and TCN 213 in Xenopus oocytes
was conducted by fellow colleagues as stipulated in chapter 2. TCN 213 was first to
be  pharmacologically  assessed,  both  non-endogenously  in  oocytes  and
endogenously in cortical cultures, solely on the basis it was the first compound to
become  commercially  available.  Nevertheless,   once  TCN  201  became
commercially available, it was demonstrated that TCN 201 was more potent than
TCN 213 as illustrated in Figure 1. This is consistent with the original study where
TCN 201 (pIC50 = 6.8) was found to be more potent than TCN 213 (pIC50 = 5.8)
(Bettini et al.  2010).  Therefore, it  was essential that I further pharmacologically
assessed TCN 201 antagonism in cortical cultures as the enhanced potency favours it
over  TCN  213  for  pharmacological  studies  (Hansen  et  al.  2012;  Hansen  et  al.
2014) and studying downstream signalling of the NMDAR  (Costa et al. 2012; Shin
et al. 2012; Hargus & Thayer 2013). 
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Figure  1:  Pharmacological  analysis  of  TCN  213  and  TCN  201  antagonism  at
GluN1/GluN2A NMDARs expressed non-endogenously.  Experiments  performed by  S.
Edman.  (A)Two-electrode voltage clamp recordings in oocytes expressing GluN1/GluN2A
NMDAR. Cells clamped at  -40 mV.  Application of glutamate and either 10 µM glycine
(left) or 30 µM glycine (right) permits steady state current to be reached.10 µM TCN 213
antagonizes this steady state current in a glycine dependent manner. (B) Same conditions as
A except 10 µM TCN 201 was utilized to antagonize steady state current. This antagonism
was again dependent on the concentration of glycine. Note that the potency of TCN 201 is
greater than TCN 213 in (A). (C) Summary of data. Both the potency of TCN 201 and TCN
213 are dependent on the concentration of glycine but TCN 201 is more potent than TCN
213 at both 10 µM and 30 µM glycine. TCN 201 (10 μM, n = 12; 30 μM, n = 8) and TCN





4.2.2 TCN 213 does not block NMDA currents in young rat cortical cultures
It has been previously demonstrated that rat cortical cultures utilized in this study
predominately express diheteromeric GluN2B NMDARs between DIV 7 to DIV 11
as demonstrated by ~75% block of whole-cell NMDA currents by 3 µM ifenprodil
(M-A Martel et al. 2009). As ifenprodil blocks a pure diheteromeric population by
~80% and a triheteromeric  GluN2A-GluN2B by ~30%,  the population must  be
predominately  diheteromeric  GluN2B.  Therefore,  this  developmental  time  point
could be used to confirm, in accordance with the heterologous Xenopus oocyte data,
that  TCN  213  does  not  block  diheteromeric  GluN2B  NMDARs  endogenously
expressed. 
To determine this, rat cortical neurons between DIV 7 – 9 were voltage-clamped at
-70mV and whole-cell NMDA currents were evoked by 50 µM NMDA and 1.5 µM
glycine. Under these conditions,  TCN 213 blocked a pure diheteromeric GluN2B
population by <5% and a pure GluN2A population by ~75% when heterologously
expressed (Figure 2).  As predicted,  TCN 213 failed to block whole-cell  NMDA
currents under these conditions but 3 µM ifenprodil reduced the steady state current
by 72±2% in excellent agreement with  (Martel  et  al.  2009).  It  can therefore be
concluded  that  TCN  213  fails  to  block  endogenous  diheteromeric  GluN2B
NMDARs as predicted from data in the heterologous system.
This was viewed as a proof of principle experiment and therefore, once TCN 201
subsequently  became  available,  the  experiment  was  not  repeated.  From  here,  I
wished to focus on TCN 213 and TCN 201 antagonism at NMDARs expressing
GluN2A NMDARs  either  by  over-expression  or  endogenous  developmental  up-
regulation. 
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Figure 2: TCN 213 shows no antagonism of NMDARs expressed in young (DIV 7-9)
cortical cultures under conditions which would block a pure diheteromeric GluN2A
population by 75%. 
(A) A rat cortical neuron was voltage-clamped at -70mV and whole-cell NMDA current was
evoked by 50 µM NMDA and 1.5 µM glycine. 10 µM TCN 213 fails to antagonize this
steady state current. Once the steady state current was re-achieved, 3 µM ifenprodil blocks
by ~75%. (B)  Summary of data. n = 12. TCN 213 fails to demonstrate antagonism at the
developmental time point DIV 7-11 suggesting little diheteromeric GluN2A NMDARs. The





4.2.3 TCN 213 can detect a developmental switch in NMDAR subunits
Developmentally  upregulated  GluN2A  subunits  can  be  incorporated  into
diheteromeric GluN2A NMDARs or triheteromeric GluN2A-GluN2B NMDARs as
discussed  in  sections  1.1  and  1.2.  It  is  now  appreciated  that  triheteromeric
NMDARs  are  largely  expressed  in  mature  hippocampal  cultures  (Tovar  et  al.
2013) and at the time, I appreciated this possibility in our cortical culture system. It
was  hypothesized  there  could  potentially  be  a  lack  of  TCN  213  antagonism in
mature  cultures  due  to  the  presence  of  triheteromeric  NMDARs;  as  the
pharmacological profile of TCN 213 at triheteromeric NMDARs was unknown, it
was possible the potency of TCN 213 at diheteromeric and triheteromeric NMDARs
was substantially different. 
Consequently, two positive controls were established. Firstly, as there is a negative
correlation between ifenprodil sensitivity and GluN2A expression (see section 1.2),
measuring  ifenprodil  sensitivity  prior  to  TCN  213  application  gives  an  indirect
measurement of GluN2A expression. Secondly, by overexpressing GluN2A, it was
hypothesized this would induce a bias towards expression of diheteromeric GluN2A
NMDARs rather than triheteromeric NMDARs. This would permit the comparison
of ifenprodil and TCN 213 sensitivities of GluN2A transfected cells  with that of
mature neurons. 
DIV 7 -10 neurons that were transfected with globin (as a positive control for the
transfection procedure) demonstrated similar average ifenprodil block (70±3%) to
untransfected cells ( see  Figure 2,  72±2%). However, in DIV 7-10 neurons than
were  transfected  with  GluN2A,  the  ifenprodil  block  drastically  decreased  to  an
average  of  37±5%  (compare  Figures  3A & 3B).  This  indirectly  confirms  that
GluN2A subunits  are  expressed  at  the  neuronal  membrane  as  the  proportion  of
diheteromeric GluN2B NMDARs has decreased. In mature neurons (DIV 14-18) the
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average  ifenprodil  block  (48±4%),  similar  to  GluN2A transfected  neurons,  was
lower than young neurons thus indicating an endogenous upregulation of GluN2A
had occurred (compare Figures 3A & 3C). 
Once  the  NMDA  steady-state  current  was  re-established  in  the  presence  of
ifenprodil, 30 µM TCN 213 was applied to all three groups and the current blocked
was normalized to the NMDA current pre-ifenprodil (Figures 3A,3B & 3C). The
data  revealed  a  highly  correlated  (negative)  relationship   (R2 =  0.87)  between
ifenprodil  block and TCN 213 block;  the cells  with the lowest  ifenprodil  block,
GluN2A transfected and mature neurons, showed the highest sensitivity to TCN 213
whereas  globin  transfected  cells  had  the  highest  ifenprodil  but  reciprocally,  the
lowest TCN 213 block. 
Therefore, it can be concluded that TCN 213 successfully detects a developmental
upregulation of GluN2A as rat cortical cultures mature under the above conditions.
Although a reduction in ifenprodil sensitivity has correlated well with an increase in
GluN2A mRNA, protein expression and a change in EPSC decay kinetics (discussed
further  in  section  1.2),  this  is  the  first  demonstration  that  a  fall  in  ifenprodil
sensitivity during development also correlates with an increase in the sensitivity of a
GluN2A antagonist that shows no antagonism at GluN2B NMDARs. 
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Figure 3: TCN 213 can detect a developmental switch in NMDAR subunits. 
All cells voltage-clamped at -70 mV. whole-cell NMDA currents evoked by 50 µM NMDA
+ 3 µM glycine. Ifenprodil used at 3 µM and TCN 213 used at 30µM. % TCN 213 block
normalized to pre-ifenprodil NMDA current. 
(A) A DIV 7 globin transfected neuron illustrating a high (70%) blockade of the whole-cell
NMDA current  by ifenprodil.  The  remaining  current  is  antagonized  little  by TCN 213
(11%). 
(B)A DIV 7  GluN2A transfected  neuron  demonstrates  a  lower  ifenprodil  block  (30%).
Remaining ifenprodil insensitive current is sensitive to TCN 213 (42% block).
(C) Mature DIV 14 neuron also shows low ifenprodil block (23%) but high TCN 213 block
(43%).
(D) Plot correlating the % ifenprodil block of each cell with the % TCN 213. There is a
strong negative correlation (R2 = 0.87)  between the ifenprodil  block and the TCN 213






4.2.4 TCN 201 can detect a developmental switch in NMDAR subunits
The previous experiment was repeated replacing 30 µM TCN 213 with 10 µM TCN
201  and  using  the  same  agonist  exposure  (50  µM  NMDA +  3  µM  glycine).
However, in this instance, I did not transfect the young (DIV 7-10) control cells with
globin as it was previously determined this not change the ifenprodil sensitivity. 
As with TCN 213, there was a highly correlated (negative) relationship  (R2 = 0.91)
between ifenprodil block and TCN 201 block  (Figure 4).  Therefore, an identical
conclusion  was  reached  in  that  under  these  conditions,  TCN  201  can  detect  a
developmental upregulation of GluN2A. 
It is now established that under the above conditions, diheteromeric NMDARs are
blocked by 91% and triheteromeric NMDARs blocked by 72% (Hansen et al. 2014).
Importantly, the  ~20% reduction in TCN 201 potency at triheteromeric NMDARs is
not great enough to exclude the possibility of a prominent triheteromeric population
contributing to the correlated relationship observed. 
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Figure 4: TCN 201 can detect a developmental switch in NMDAR subunits at 3 µM
glycine. All cells voltage-clamped at -70 mV. whole-cell NMDA currents evoked by 50 µM
NMDA + 3 µM glycine. Ifenprodil used at 3 µM and TCN 201 used at 10 µM. % TCN 201
block normalized to pre-ifenprodil NMDA current. 
(A) A DIV 7 neuron illustrating a high (82%) blockade of the whole-cell NMDA current by
ifenprodil.  The remaining current is antagonized little by TCN 201 (4%).  (B)A GluN2A
transfected  neuron  demonstrates  a  lower  ifenprodil  block  (14%).  Remaining  ifenprodil
insensitive current is sensitive to TCN 201 (57% block).  (C)  Mature DIV 14 neuron also
shows low ifenprodil block (39%) but high TCN 213 block (25%).(D) Plot correlating the %
ifenprodil block of each cell with the % TCN 201. There is a strong negative correlation (R2
= 0.91)  between  the  ifenprodil  block  and  the  TCN 201 block.  n  =  7  for  DIV 7  –  10








4.2.5  At  a  higher  glycine  concentration,  TCN  201  potency  is  different  at
GluN2A transfected and mature neurons
The  previous  experiments  demonstrated  TCN 213 and  TCN 201  could  detect  a
developmental  upregulation  of  GluN2A when  3  µM glycine  was  used  as  a  co-
agonist. However, as the EC50 for glycine at GluN2A NMDARs is 1.31 µM and 0.72
at GluN2B NMDARs (P. E. Chen et al. 2008) at 3 µM glycine, there is still a bias
towards  the  activation  of  GluN2B NMDARs.  Therefore,  I  wished  to  repeat  the
experiment with a 10-fold increase in glycine concentration. 
However, at 30 µM glycine, it was soon apparent that TCN 201 antagonism was not
consistent between mature neurons. Mature DIV 17 neurons were recorded on the
same day (Figure 5A & B), and despite having similar ifenprodil sensitivities (A =
40%, B=42%) the % TCN 201 block was  ~3 times greater in the neuron illustrated
in Figure 5B. There was also a difference between mature and GluN2A transfected
cells. Again, recorded on the same day, a mature DIV 21 (Figure 5C)  and a DIV 7
GluN2A transfected neuron(Figure 5D)  have similar  ifenprodil  blocks (25% and
24% respectively) but the GluN2A transfected cell had ~3 times the TCN 201 block.
A summary of the data is illustrated in Figure 5E. There was a negative correlation
(R2 = 0.63) between ifenprodil bock and TCN 201 block but this relationship was
less strong than at 3 µM glycine (R2 = 0.91).  However, it is obvious from the data
that all the GluN2A transfected cells have a low ifenprodil block and a relatively
consistent TCN 201 block whereas there is a wider spread of TCN 201 antagonism
in mature  cells  that  have  a  low ifenprodil  block.  It  was  hypothesized the wider
spread in TCN 201 block in mature neurons was because at a higher concentration
of glycine, TCN 201 antagonizes triheteromeric NMDARs to a lesser extent than
diheteromeric  NMDARs;  I  predicted  the  GluN2A  transfection  promotes  the
formation  of  diheteromeric  GluN2A NMDARs and hence  a  relatively consistent
TCN 201 block. Nevertheless,  a more qualitative analysis is needed to test the  
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Figure 5: TCN 201 antagonism at higher 30 µM glycine
All cells voltage-clamped at -70 mV. whole-cell NMDA currents evoked by 100 µM
NMDA + 30 µM glycine. Ifenprodil used at 3 µM and TCN 201 used at 10µM.. %
TCN 201 block normalized to pre-ifenprodil NMDA current.  
(A + B) Illustration of two mature DIV 17 recorded on the same day. Although both
neurons  have  similar  ifenprodil  sensitivities  (A  =  40%,  B=42%)  the  neuron
illustrated in B has a greater TCN 201 block (20%) compared to than in neuron B
(6%). 
(C + D) Illustration of a DIV 21 mature neuron (C) and a DIV 7 neuron transfected
with  GluN2A (D)  recorded  on  the  same.  Although  both  neurons  have  similar
ifenprodil  sensitivities (C = 25%, D=24%) the GluN2A transfected neuron has a
greater TCN 201 block (34%) compared to the mature DIV 21 neuron (12%). 
(E) Plot correlating the % ifenprodil block of each cell with the % TCN 201. There
is a negative correlation (R2 = 0.63) between the ifenprodil block and the TCN 201
block. n = 13 for GluN2A transfected. n = 17 for DIV 14+.
…....................................................................................................................................
hypothesis  that  GluN2A  transfected  and  mature  neurons  are  differentially
antagonized by TCN 201.
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4.2.6 Modelling approaches indicate  presence of  triheteromeric NMDARs in
mature neurons
There is a need to qualitatively test the hypothesis that at 30 µM glycine, the TCN
201 block at GluN2A transfected cells is consistent with a diheteromeric GluN2A
population whereas mature cells demonstrate a wider range of TCN 201 antagonism
due to a prominent triheteromeric population. 
By  assuming  a  complete  diheteromeric  GluN2A and  GluN2B  population,  it  is
possible to determine the relationship between the ifenprodil block and the TCN 201
block of the ifenprodil insensitive current. This model would therefore permit the
comparison of an expected TCN 201 block for a diheteromeric GluN2A population
with that of the actual recorded value; a close fit with this model would suggest the
neuron expresses a large diheteromeric GluN2A population whereas the greater the
deviation  from  the  model,  the  more  likely  a  triheteromeric  GluN2A-GluN2B
populations exists. 
The  prediction  was  created  by  determining  the  linear  relationship  between  the
GluN2A and GluN2B fractions with their respective % TCN 201 and % ifenprodil
blocks (Figure 6A). The predicted  % TCN 201 block of the whole-cell NMDA
current can be derived from the linear equations and then subsequently, the % TCN
201 block of the ifenprodil insensitive current (Figure 6B). Both predictions are of
course  dependent  on  the  maximal  TCN  201  block  for  a  complete  GluN2A
population expressed non endogenously; at 30 µM glycine, the maximal TCN 201
block was determined to be 50% (Edman et al. 2012). Under these conditions, the
relationship  between  the  % ifenprodil  block  and  the  % TCN 201  block  of  the
ifenprodil insensitive current is illustrated in Figure 6C. 
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Figure  6: Predicting % TCN 201 block under assumption that  only  diheteromeric
GluN2A and GluN2B NMDARs are expressed. (A)  The linear relationship between the
GluN2A and GluN2B fractions with their respective % TCN 201 and % ifenprodil blocks. 
(B)The predicted % TCN 201 block of the whole-cell NMDA current can be derived from
the linear equations (left) and then subsequently, the % TCN 201 block of the ifenprodil
insensitive current can be determined (right)
(C)The relationship between the % ifenprodil block and % TCN 201 block of ifenprodil
insensitive  current.  At  30 µM glycine,  the  maximal  TCN 201 block of  a  pure GluN2A
diheteromeric population expressed non-endogenously is 50%.  
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To determine how well each individual neuron fits the diheteromeric prediction, the
recorded TCN 201 block was normalized to the diheteromeric predicted block. An
analysis of the average normalized value reveals the GluN2A transfected cells fit
this model extremely well  (0.95±5) whereas the mature neurons to a significantly
less  extent  (0.39±9)  (Figure  7A).  This  confirms  the  hypothesis  that  GluN2A
transfected and mature neurons are differentially antagonized by 10 µM TCN 201 at
30 µM glycine as a consequence of GluN2A transfected neurons expressing a higher
proportion of diheteromeric GluN2A NMDARs. Nevertheless, it is evident from the
spread of  data  that  some mature neurons exhibit  a  TCN 201 antagonism that  is
consistent  with  a  prominent  diheteromeric  GluN2A population.  It  is  therefore
proposed that mature neurons can express a wide complement of diheteromeric and
triheteromeric NMDARs. 
Finally, it is important to reiterate a caveat of the current approach. Approximately
30% of any triheteromeric GluN2A-GluN2B NMDAR current had already been pre-
blocked by ifenprodil prior to antagonism by TCN 201. This does not change the
conclusions derived from the data as both GluN2A transfected and mature neurons
were treated identically. Nevertheless,  it does suggest that where reduced TCN 201
antagonism  was  observed,  it  is  likely  this  is  an  underestimation  as  30%   of
triheteromeric NMDARs had been pre-blocked by ifenprodil.
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Figure  7: Modelling  10  µM  TCN  201  at  30  µM  glycine  antagonism  with
predicted diheteromeric block.
*p < 0.05, Student unpaired t-test 
 n = 13 for GluN2A transfected. n = 15 for DIV 14+
(A) The TCN 201 block of the ifenprodil insensitive current was calculated for each
cell in  figure 4E under the condition the ifenprodil block <60% (2 DIV 14+ cells
were  excluded).   Concurrently,  under  the  assumption  that  only  diheteromeric
GluN2A and GluN2B NMDARs are expressed, the predicted TCN 201 block the
ifenprodil  insensitive  current  was  calculated  using  the  cell's  ifenprodil  block.
Normalizing the recorded block with the predicted block determines to what extent
GluN2A diheteromeric NMDARs are expressed. A significant difference between
GluN2A transfected (0.95±5)  and mature DIV 14+  (0.39±9) was observed. Due to
the greater deviation in data recorded for DIV 14+ neurons, it is proposed that a










It can therefore be concluded that at 3 µM glycine, 30 µM TCN 213 and 10 µM
TCN 201 can detect a developmental upregulation of GluN2A during the maturation
of cortical cultures. The highly correlated negative relationship between ifenprodil
sensitivity  and  TCN  201/213  sensitivity  in  low  glycine  suggests  that  either
triheteromeric NMDARs are not expressed to a great extent or TCN 201 and TCN
213 have  similar  potencies  at  diheteromeric  and triheteromeric  NMDARs under
these  conditions.  Regarding  TCN  201,  it  is  now  established  that  triheteromeric
NMDARs only have a 20% reduction in antagonism compared to diheteromeric at 3
µM glycine; it  is likely such as small  difference in potency would still  permit a
highly  correlated  relationship  between  GluN2B  antagonism  and  GluN2A
antagonism regardless if triheteromeric or diheteromeric NMDARs are expressed. 
Moreover,  increasing  the  glycine  concentration  10-fold  to  30  µM  caused  the
correlated  negative  relationship  between  ifenprodil  and  TCN  201  sensitivity  to
decrease.  By  modelling  the  data  on  a  predicted  TCN  201  block  of  a  pure
diheteromeric population, it was revealed that the loss of correlation was due to a
lack  of  diheteromeric  GluN2A  NMDARs  in  mature  DIV  14+  neurons;  this
conclusion could be reached as transfecting GluN2A permits a TCN 201 antagonism
in excellent accordance with a diheteromeric population. It is assumed the lack of
diheteromeric  GluN2A in  mature  neurons  is  due  to  a  prominent  triheteromeric
population. 
However, for this conclusion to be reached it is imperative that the difference in
TCN 201 potency between diheteromeric and triheteromeric NMDARs at 30 µM
glycine is far greater than the ~20% observed at 3 µM. The determination of this is
essential  for a full  and comprehensive interpretation of the data.  Nevertheless,  a
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proposed model from the data presented is summarized in  Figure 8. Determining
the  robustness  of  this  model  is  essential  for  understanding  NMDAR  mediated
signalling as if correct, it would expand the small but growing body of evidence that
suggests triheteromeric NMDARs may be the prominent subtype expressed at
hippocampal synapses in culture (Tovar et al. 2013) and hippocampal in vitro 
slices(Gray et al. 2011; Rauner & Kohr 2011).  This has yet to be demonstrated in 
the cortical culture system used here. 
Figure  8: Proposed  developmental  changes  in  GluN2A  and  GluN2NB
antagonism by TCN 201 during cortical culture development.  
(A) At low glycine concentrations, TCN 201 blocks whole-cell NMDA currents in a
consistent manner which is dependent on the ifenprodil block of the cell; the TCN
201 blockade is consistent due to a high TCN 201 potency at both diheteromeric and
triheteromeric NMDARs.
(B) At higher glycine concentrations the TCN 201 antagonism is dependent on the
ifenprodil block of the cell and also the relative proportion of diheteromeric and
triheteromeric expressed; it  is  assumed there is  a greater  difference in TCN 201
potency at diheteromeric and triheteromeric NMDARs at higher glycine.   
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4.3.2 The relevance of the cortical culture system in detecting developmental
changes in GluN2 subunits
The network activity in culture system utilized in this study is artificially created;
this  suggests  specific  electrical  input  is  not  required  for  the  developmental
upregulation  of  GluN2A.  Furthermore,  chronic  silencing  of  network  activity  in
hippocampal  slice  cultures  induces  synaptic  scaling,  via  both  AMPARs  and
NMDARs,  without  altering  the  subunit  composition  of  NMDARs  (Arendt  et  al.
2013).  Nevertheless, as discussed further in  section 1.2.2,   young hippocampal
neurons subjected to an LTP protocol can have a rapid upregulation of GluN2A at
the  synapse  in  minutes  (Bellone  & Nicoll  2007;  Matta  et  al.  2011) and  visual
experience has been shown the increase the expression of the GluN2A subunit in the
visual cortex  (Quinlan et  al.  1999).  Altogether,  it  is  feasible that  there is  a cell-
autonomous upregulation of GluN2A which can be modified by synaptic plasticity
upon specific patterns of electrical activity. 
4.3.3 Utilizing TCN 201 to antagonize GluN2A-dependent signalling 
As  previously  discussed,  the  use  of  NVP-AAM077  to  study  GluN2  dependent
signalling in neuroprotection, excitotoxicity and synaptic plasticity has led to the
generation of type I errors. That is,   NVP-AAM077 was used at  a concentration
which was intended to selectively block GluN2A but in fact, blocked a substantial
proportion of both GluN2A and GluN2B leading to contradictory results regarding
subunit  dependent  signalling.  On  the  other  hand,  as  TCN  201  is  an  allosteric
modulator specifically at the GluN2A subunit, this has functional consequence that
the  compound  shows  no  antagonism at  the  other  three  GluN2 subunits.    This
completely removes the possibility of type I errors and is undoubtedly the major
advantage of TCN 201. 
However, the major drawback of TCN 201 for blocking NMDARs signalling is the
dependency  of  glycine/D-serine  present  at  synaptic  and  extrasynaptic  sites.
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Commercially  available  media,  such  Neurobasal-A and  DMEM,  have  400  µM
glycine present and TCN 201 would give no antagonism of NMDAR currents under
these glycine concentrations. Nevertheless, several studies have utilized TCN 201 in
vitro using such media (Costa et al. 2012; Shin et al. 2012; Hargus & Thayer 2013).
Whereas neuronal and glial cells will take-up and metabolize glycine thus lowering
the glycine concentration, to what rate this occurs is not clear. Even if glycine and
D-serine free media was utilized, both astrocytes and neurons will release and take-
up the co-agonist  and the manner in which this occurs is multifactorial;  the cell
density of the culture and the neuron:astrocyte ratio would need to be considered.
Lastly, any perturbation of the system such as inducing excitotoxicity,  would have
to be checked that it does not cause a rapid release of glycine/D-serine.  Altogether,
it is evident that the use of TCN 201 to investigate NMDAR signalling unfortunately
suffers  from  the  opposite  problem  of  NVP-AAM077;  potential  antagonism  of
GluN2A  NMDARs  by  TCN  201  can  be  masked  by  high  concentrations  of
glycine/D-serine leading to potential type II errors. 
Another caveat is that TCN 201 has limited solubility in salt solutions such as ACSF
and  therefore  this  may  limit  the  use  of  TCN  201  to  study  NMDARs  in  vivo.
Nevertheless, a recent study successfully utilized TCN 201 and ifenprodil separately
to  reduce  drug seeking  behaviour  (Gipson et  al.  2013).  Of  note,  ifenprodil  was
administered systemically whereas TCN 201 was micro-injected into the nucleus
accumbens core; it was not stated whether the micro-injection was a prerequisite due
to the poor solubility of TCN 201. Regardless, it is encouraging that alterations in
behaviours  can  be  induced by selective  antagonism of  NMDARs containing  the
GluN2A subunit. 
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4.3.4 Concluding Remarks 
The data presented in this chapter is noteworthy as it is the first pharmacological
demonstration of a developmental change in the expression of GluN2 subunits using
antagonists that are entirely specific for GluN2A and GluN2B. Further research into
the  pharmacological  profile  of  TCN  201  at  triheteromeric  NMDARs  will  be
imperative  in  interpreting  TCN  201  antagonism  of  endogenously  expressed
NMDARs.  Meticulous  measurement  of  glycine  and  D-serine  at  synaptic  and
extrasynaptic sites is needed to determine the potency of TCN 201 antagonism; this
is the major limitation of utilizing TCN 201 to dissect GluN2A-dependent NMDAR
signalling. 
The pharmacological demonstration of the developmental upregulation of GluN2A
presented here strengthened the rationale of utilizing cortical cultures derived from
knock-in  mice  whereby  the  CTD  of  GluN2A had  been  replaced  with  that  of
GluN2B. The consequence of this genetic alteration in the developmental expression




The role of the GluN2






It was demonstrated in chapter 4 the cortical culture system is a useful tool to study
the molecular underpinnings of the developmental switch in GluN2 subunits. 
One such mechanism involves Ca2+ influx through GluN2B containing NMDARs
starting a  negative feedback loop which ultimately promotes  the upregulation of
GluN2A containing NMDARs indirectly by dampening the expression of GluN2B-
NMDARs at the membrane as illustrated in Figure 1. 
Figure 1: Ca2+ influx through GluN2B-NMDARs can initiate a negative feedback
loop which limits GluN2B expression at the membrane. 
In greater detail, Ca2+ influx activates CaMKII where it binds to the GluNB CTD in
the  region  1290-1309  (Strack  et  al.  2000) and  can  subsequently  promote  the
phosphorylation  of  ser1480  by  CK2  (Chung  et  al.  2004).  Subsequently,  CK2
phosphorylates the C-terminus of GluN2B at S1480 thus disrupting the interaction
of GluN2B CTD with MAGUK proteins which ultimately leads to the NMDAR
being endocytosed at extrasynaptic sites (Sanz-Clemente et al. 2010; Sanz-Clemente
et al. 2013). The endocytosis is itself regulated by SAP-102 which can promote the
retrieval of GluN2B from the membrane via its N-terminus binding to the GluN2B
CTD (Chen et al. 2012). Secondly, the GluN2B CTD is trafficked through recycling
endosomes  whereas  the  GluN2A  is  sorted  into  late  endosomes  destined  for
degradation in non-neuronal cells  (Tang et al. 2010). Lastly, there is strong evidence
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Ca2+ influx activates CaMKII which promotes CaMKII  
binding  to the GluNB CTD 
CaMKII binding to the GluN2B CTD promotes the 
phosphorylation of the GluN2B CTD at S1480 by CK2
Phosphorylation of S1480 promotes the endocytosis of 
GluN2B containing NMDARs thus favouring GluN2A-
containing NMDARs exprressed at the membrane
that PSD-95 is necessary for the selective forward trafficking of GluN2A containing
NMDARs to the synapse  (Elias et al. 2008). However, although the interaction of
PSD-95 with the PDZ domain of the GluN2A subunit is the most studied, it has yet
to be proven that the forward trafficking is dependent on the GluN2A CTD. 
However the use of protein overexpression, which can result in off-target or non-
specific  protein  interactions,  was  utilized  extensively  in  the  above  studies.  To
circumvent this issue, an elegant genetic knock-in approach whereby the C-terminal
of  GluN2A  was  replaced  with  that  of  GluN2B  (named  GluN2A2B(CTR))  and
reciprocally,  the GluN2B CTD with that  of  GluN2A (named GluN2B2A(CTR))  was
implemented(Ryan et al. 2013). This genetic alteration in the GluN2A2B(CTR) mouse
line would prevent the selective CK2-dependent endocytosis of GluN2B-NMDARs
as GluN2A2B(CTR) neurons would also be subjected to CK2 phosphorylation at S1480.
Consequently, in GluN2A2B(CTR) neurons, both GluN2A and GluN2B will be undergo
CTD regulated endocytosis at the same rate; if selective endocytosis of GluN2B via
the CTD is essential for the upregulation of GluN2A at the neuronal membrane then
this developmental upregulation will be disrupted in GluN2A2B(CTR) neurons.
I  wished  to  test  the  above  hypothesis  utilizing  the  GluN2A2B(CTR  mouse  and the
cortical culture system utilized in  chapter 4;   a developmental loss of ifenprodil
potency, rather than a developmental gain of TCN 201 potency, was decided as the
assay to determine the upregulation of GluN2A as ifenprodil sensitivity does not
depend on the concentration of the co-agonist glycine/D-serine. If the hypothesis
was correct, and there was an impedence in the upregulation of GluN2A, then there
would a reduced loss of ifenprodil sensitivity during cortical culture maturation. In
this  case,  no  further  experiments  were  planned  as  there  would  be  two  distinct
populations  of  NMDARs in the  WT and GluN2A2B(CTR  neurons.  However,  if  the
hypothesis was incorrect, then it would be possible to determine if the GluN2A2B(CTR
neurons had altered responses to excitotoxic insults or the induction of immediate
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early genes by synaptic activity as summarized in Figure 2. 
Figure 2: The plan and development of experimental hypotheses in chapter 5. 
As  discussed  in  sect  ion  1.4.3,  it  has  previously  been  demonstrated  that  the
reciprcoal CTD switch from this study, GluN2B2A(CTR) neurons,  are less vulnerable to
NMDA-dependent excitotoxicity both in vitro and in vivo; this confirms the GluN2B
CTD  preferentially  couples  to  excitotoxic  signalling  (Martel  et  al.  2012).
Interestingly,  the reduction in  excitotoxicity afforded by replacing GluN2B CTD
with the GluN2A CTD could be overridden by higher Ca2+ influx. This suggests that
at extremely high intracellular Ca2+ concentrations,  NMDARs signalling dependent
on the GluN2 CTD may be irrelevant to the biological outcome of an excitotoxic
insult possibly because of the direct disruption of mitochondrial health by Ca2.
Furthermore, transfection of GluN2A2B(CTR)  in young DIV 9-10 neurons induced a
greater vulnerability to excitotoxicity than neurons transfected with WT GluN2A
(Martel et al. 2012). The enhanced excitotoxicity in over-expressing GluN2A2B(CTR)
neurons is in excellent accordance with the overwhelming evidence of decreased
excitotoxicity in the reciprocal neurons derived from the GluN2B2A(CTR) mouse line.
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Altogether, it is logical to hypothesize the converse, an increrase in excitotoxicity, is
would be present in GluN2A2B(CTR) neurons. 
As discussed further in section 1.4.2, CREB is a master transcriptional regulator of
neuroprotective genes and itself is regulated via phosphorylation by nuclear Ca2+-
activated  CaM kinases;  chelating  Ca2+ specifically  in  the  nucleus  blocks  CREB
mediated transcription of neuroprotective genes  (Hardingham et al.  1997).   At a
developmental  time point  where diheteromeric  GluN2B NMDARs are dominant,
synaptic activity can result in the activation of CREB and provide neuroprotection
which is maintained as GluN2A is developmentally upregulated (Martel et al. 2009a;
Hardingham  &  Bading  2010).  Moreover,  although  disrupting  the  PDZ  ligand
domain on the GluN2B CTD with TAT-NR2B9c reduces excitotoxicity, it does not
impair the induction of the CREB target genes by synaptic activity  (Martel et al.
2009b); this suggests the PDZ domain of the GluN2B CTD is not necessary for
NMDAR activity to modify the phosphorylation of CREB. Furthermore, Ca2+ influx
through  L-type  Ca2+  channels  via  depolarization  (Weick  et  al.  2003) or  agonist
activation utilizing the agonist FPL 64176 (Rajadhyaksha et al. 1999) can also result
in  CREB activation.  Although  Ca2+ can  activate  CREB via  slower  and  indirect
mechanisms such as via ERK, it is evident that nuclear Ca2+ concentrations itself is
the main determinant in the transcription of neuroprotective genes  (Bading 2013).
Furthermore,  nuclear  CaM  kinases  activated  by  Ca2+ can  also  promote  the
transcription of other neuroprotective transcription factors such as NPAS4 (Qiu et al.
2013). 
In  disagreement  with  the  above,  It  has  been  reported  that  GluN2A containing
NMDARs  exclusively  mediate  neuroprotective  signalling  in  mature  neurons
regardless  of  their  membrane  location  (Liu  et  al.  2007) and  that  GluN2A and
GluN2B differentially regulate the induction of the CREB target gene brain-derived
neurotrophic factor (BDNF) upon synaptic activity  (Chen et  al.  2007).  However,
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both  these  studies  utilized  a  concentration  of  NVP-AAM077 which  blocks  both
GluN2A and GluN2B NMDARs, with the intention of selectively blocking GluN2A
thus making the data difficult to interpret. 
It is imperative that the molecular underpinnings of neuroprotection are understood
in  order  that  they  are  minimally  antagonized  by therapeutic  strategies  aimed  at
blocking excitotoxic signalling. Therefore, I wished to test the hypothesis that there
will be no difference in the induction of immediate early genes by synaptic activity
between WT and  GluN2A2B(CTR) neurons; the reasoning being is that nucelar Ca2+
concentration, rather than GluN2-dependent signalling,  determines the transcription
of neuroprotective genes.   
To  summarize  the  findings  from the  study,  the  whole-cell  NMDA currents  and
ifenprodil  sensitivities  of  GluN2A2B(CTR) cultures  were  not  significantly  different
from WT cultures indicating a developmental upregulation of GluN2A had occurred.
Furthermore, the proportion of NMDARs at synaptic and extrasynaptic sites was not
altered  in  GluN2A2B(CTR) cultures  and  a  loss  of  GluN2B  at  both  synaptic  and
extrasynaptic sites could be detected in both WT and GluN2A2B(CTR)  cultures. As it
was  established  that  replacing  the  CTD  of  GluN2A with  GluN2B  induced  no
impairment  in  the expression of NMDARs, it  was then subsequently possible  to
determine if there were any deficits in excitotoxic and neuroprotective signalling.
GluN2A2B(CTR) cultures were more vulnerable to NMDA-dependent excitotoxicity in
an agonist-dependent manner but showed no impairment in the expression of several
immediate early genes triggered by synaptic activity.
 
Altogether, it can be concluded that when both GluN2A and GluN2B are subjected
to  regulation  by  CK2  and  other  specific  post-translational  modifications  at  the
GluN2B CTD, the developmental upregulation of GluN2A still  occurs indicating
that CTD-subtype specific interactions are not required contrary to current models.
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5.2.1 whole-cell NMDA currents and ifenprodil sensitivities are unchanged in
mature GluN2A2B(CTR) cultures
As the data in  chapter 4 demonstrated a developmental upregulation of GluN2A
between DIV 7 and DIV 14 in rat cortical cultures, sister WT and GluN2A2B(CTR)
cultures  were prepared and maintained in  parallel  for a  minimum of 15 days  to
permit the endogenous upregulation of GluN2A to occur.
Although  the  NMDA current  density  alone  is  a  valuable  tool  to  determine  the
proportion of NMDARs expressed in young neurons, where mainly diheteromeric
GluN2B NMDARs are expressed  (see Puddifoot et al. 2012 for an example), it is
difficult  to  do  the  same in  mature  cultures  as  the  upregulation  of  GluN2A into
triheteromeric and diheteromeric NMDARs will introduce NMDARs with different
biophysical properties. Nevertheless, NMDA currents were evoked under saturating
agonist exposure (150 µM NMDA + 100 µM glycine) to determine the NMDAR
current density of each neuron and there was no significant difference between WT
and GluN2A2B(CTR) cultures (Figure 3A). 
A more  valuable  measurement  to  determine  the  developmental  upregulation  of
GluN2A in GluN2A2B(CTR) neurons is by the measurement of the ifenprodil sensitivity
of the whole-cell NMDA current. Similar to the rat cortical cultures in  chapter 4,
both  WT  and GluN2A2B(CTR)  cultures  contained  neurons  with  a  wide  range  of
ifenprodil sensitivities as can be observed in Figure 3B. Nevertheless, as young DIV
7-10 neurons consistently have ifenprodil  block of  around ~75% indicative of  a
predominately  diheteromeric  GluN2B  population,  the  wide  spread  of  ifenprodil
sensitivities in both WT and GluN2A2B(CTR) cultures demonstrate many neurons have
incorporated  GluN2A  containing  NMDARs  into  the  neuronal  membrane.
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Importantly,  there  was  no  significant  difference  between  WT and  GluN2A2B(CTR)
cultures confirming the developmental incorporation of GluN2A-NMDARs is not
impeded by replacing the GluN2A CTD with that of GluN2B. 
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Figure 3: Replacing the CTD of GluN2A with GluN2B does not affect the whole-cell
NMDA currents or  ifenprodil sensitivity of mature neurons.
All cells  recorded between DIV15-16 and were voltage-clamped at  -60 mV. Recordings
only made if it was possible to record sister WT and GluN2A2B(CTR) cells on the same day. 
(A) whole-cell  NMDA currents  in   sister  WT and  GluN2A2B(CTR)  were  evoked  under
saturating agonist exposure( 150 µM NMDA + 100 µM glycine) and the current measured
normalized  to  the  cell's  capacitance  to  give  the  NMDA current  density.  There  was  no
significant difference between WT  and GluN2A2B(CTR) neurons.  
(B) In the same neurons as  A,  the whole-cell NMDA current was antagonized by 3 µM
ifenprodil  and  the  ifenprodil  block  (%)  of  each  neuron was  determined.  There  was  no
significant difference between WT and WT and GluN2A2B(CTR) neurons. 
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Student t-test(2-tailed): p = 0.70
A B
5.2.2 The proportion and subunit  composition  of  NMDARs at  synaptic  and
extrasynaptic sites are unchanged in mature GluN2A2B(CTR) cultures
The  developmental  upregulation  of  GluN2A occurs  during  a  period  of  intense
synaptogenesis  and  spinogenesis  and  in  juxtaposition,  NMDARs  switch  from
existing  as  predominately extrasynaptic  to  synaptic  (discussed  further  in  section
1.2.3).  Therefore,  it  has  largely  been  hypothesised  that  the  two  developmental
changes are correlated and an increase in the content of synaptic NMDARs is  a
consequence of the upregulation of GluN2A.  Ultimately, this has led to a dogma
that  asserts  that  GluN2A-NMDARs  are  specifically  expressed  at  the  synapse
whereas GluN2B-NMDARs are expressed extrasynaptically  (see Lau & Zukin 2007
for an excellent review). However,  this has been challenged in recent years by the
observation there is a developmental loss of ifenprodil sensitivities at extrasynaptic
NMDARs (Thomas et al. 2006; M-A Martel et al. 2009). 
Truncation  of  the  GluN2  CTD  has  been  proposed  to  impair  synaptic  but  not
extrasynaptic  targetting  of  NMDARs  (Steigerwald  et  al.  2000).   However,  this
conclusion  was  largely  obtained  utilizing  electrophysiology,  and  it  is  now
recognized  truncation  of  the  GluN2  CTD  alters  the  channel  kinetics  of  the
NMDAR(Maki et al. 2012; Punnakkal et al. 2012). Furthermore,  the definition of
extrasynaptic  NMDARs  in  this  study  were  defined  as  those  activated  by  fast
application  of  glutamate  in  nucleated  whole-soma  patches  of  CA1  pyramidal
neurons which is an approach not adopted in subsequent studies. On the other hand,
over-expression  of  C-terminally  truncated  GluN2A in  NR2A−/− neurons  permits
GluN2A to be expressed at the synapse suggesting the GluN2A CTD is not essential
for localization at the synapse ; improper localization due to over-expression is of
course a caveat of this approach (Thomas et al. 2006). 
Therefore  as  the  role  of  the  GluN2A CTD  in  synaptic  targeting  to  membrane
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locations is unclear, I wished to test the hypothesis that replacing the GluN2A CTD
with  that  of  GluN2B  would  not  disrupt  the  synaptic  targetting  of  NMDARs
(GluN2A2B(CTR) NMDARs).  As the ifenprodil sensitivity of all NMDARs expressed
on a neuron (synNMDARS + exNMDARs) varies greatly between neurons in both
WT and GluN2A2B(CTR) cultures (Figure 3B), if one were to only measure ifenprodil
sensitivity at exNMDARs then a similar high sample size would be required to be
confident in any statistical measurements between the WT and GluN2A2B(CTR)  being
robust. A more elegant approach is to correlate the ifenprodil sensitivity of the whole
neuron  (synNMDARs  +  exNMDARs)  with  that  of  the  ifenprodil  sensitivity  at
exNMDARs  alone.  This  would  require  the  experimental  paradigm illustrated  in
Figure 4. 
 
Figure 4: Proposed experimental paradigm for measuring ifenprodil sensitivity of the whole-
cell NMDA current then subsequently at exNMDARs only. 
However,  after  the  measurement  of  the  ifenprodil  sensitivity  of  the  whole-cell
NMDA current, TTX must washout in order that phasic activity permits MK-801 to
block synNMDARs in a time period of around 5 minutes. Furthermore, after 3 µM
ifenprodil  has  antagonized the whole-cell  NMDA current,  it  must  be completely
washed out in order to selectively measure ifenprodil sensitivity at exNMDARs. 
Therefore, I utilized WT cultures at a developmental time point (DIV 7), where only
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Promote phasic activity in ACSF containing 1mM MgCl
2
/50 µM Bicuculline/ 10 µM MK-801 
Determine the % antagonism of the whole cell NMDA current by 3 µM ifenprodil  in 
ACSF containing 0-Mg2+/ 300 nM TTX
300 nM TTX must washout
3 µM ifenprodil must washout out
Determine the % antagonism of the extrasynaptic NMDA current by 3 µM ifenprodil  in 
ACSF containing 0-Mg2+/ 300 nM TTX
diheteromeric GluN2B NMDAR are expressed, to test the pharmacological wash-
out profiles of TTX and ifenprodil are suitable for the proposed above experiment.
To achieve this, the ifenprodil sensitivity of a neuron was determined in Mg2+-free
ACSF  with  TTX  present  in  the  voltage-clamp  configuration.  Subsequently,  the
neuron was then switched to a reciprocal Mg2+-containing but lacking TTX ACSF
and allowed to fire  at  the cell's  resting membrane potential  in  the current-clamp
configuration.  During  the  first  2  minutes  of  the  “wash”  period,  all  the  neurons
recorded fired bursts of action potentials indicating TTX had successfully washed
out (Figure 5B shows an illustrative burst firing). After the first action potential,
the wash period was extended for a further 5 minutes, and the ifenprodil block of the
NMDA current was re-determined under identical conditions and was found not to
be  significantly  different  from  the  initial  ifenprodil  block  (Figure  5A).  It  can
therefore  be  concluded  that  measuring  ifenprodil  sensitivity  of  the  whole-cell
NMDA  current  (synNMDARs  +  exNMDARs)  and  then  subsequently  at
exNMDARs  alone  is  a  feasible  pharmacological  approach.  This  data  also
demonstrates that at DIV 7, there is very little rundown of NMDA currents (<10%)
during the wash period. 
Nevertheless, run down of NMDA currents may be greater in more mature neurons.
To test this, WT neurons derived from CD1 mice, were cultured to DIV 16-18. For
each  cell,  the  whole  cell  NMDA current  was  determined  followed by the  wash
period described above, either in the absence or presence of 10 µM MK-801. In the
absence of MK-801 during the wash period, there was a 7% decrease in whole cell
NMDA currents attributed to run down. However, when MK-801 was included in
the  wash period  to  block  synNMDARs,  a  62% reduction  in  whole  cell  NMDA
currents was observed (data not shown). This illustrates that run down of NMDA
currents contributes approximately 11% the overall synaptic blockade by MK-801. 
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Figure 5: Determining the wash-out profile of ifenprodil and TTX.
(A)All neurons were recorded on DIV 7 and voltage-clamped at -60mV. In the presence of 300 nM
TTX and 0-Mg2+, whole-cell NMDA current was evoked (by 150 µM NMDA + 100 µM glycine) and
then  subsequently  blocked  by  3  µM  ifenprodil.  The  neurons  were  then  switched  to  an  ACSF
containing 1 mM MgCl2 but lacking TTX  in the current-clamp configuration for a 5 minute “wash”
period thus permitting the firing of action potentials. Finally, the whole-cell NMDA current was re-
determined in the voltage-clamp configuration which was then subsequently blocked by ifenprodil.
The ifenprodil block pre and post   “wash” period was 80±2% and 75±3% respectively confirming
the ifenprodil  block was removed during this time. P > 0.05 paired student test (2-tailed).  n = 6
neurons.
(B) During the wash period, neurons robustly fire bursts of action potentials indicating TTX block




I  then  turned  my attention  to  utilizing  this  pharmacological  approach,  with  the
inclusion of 10 µM MK-801 during the phasic activity to block synNMDARs,  in
mature WT and GluN2A2B(CTR) cultures as illustrated in Figure 6A. In both WT and
GluN2A2B(CTR)  cultures,  10 µM MK-801 blocked  ~80% of the whole-cell NMDA
currents during phasic activation indicating that the ratio of synaptic:extrasynaptic in
mature  neurons  is  approximately  4:1.  Importantly,  there  was  no  significant
difference between the two cultures (Figure 6B).  Furthermore, there was a clear
positive  correlation  between  the  ifenprodil  sensitivity  of  the  whole-cell
(synNMDARs + exNMDARs) with exNMDARs alone in both cultures (Figure 6C)
indicating  GluN2A containing  NMDARs  are  present  at  extrasynaptic  sites. By
determining the ratio of ifenprodil sensitivity of extrasynaptic:whole-cell for each
neuron, the average values for WT (1.22±0.05) and GluN2A2B(CTR) (1.13±0.03) reveal
that there is a small but preferential loss of GluN2B at synNMDARs yet there was
no significant between WT and GluN2A2B(CTR) cultures (Figure 6D). 
Altogether,  it  can  be  concluded  that  replacing  the  GluN2A CTD does  not  alter
synaptic targetting of the NMDAR to synaptic and extrasynaptic sites. This has the
important  consequence  that  any activation  of  the NMDAR will  result  in  similar
spatial Ca2+ influx in both WT and GluN2A2B(CTR) cultures thus permitting the study
of downstream signalling. 
124
Figure 6: The proportion and subunit composition of NMDARs at synaptic and extrasynaptic
sites are unchanged in mature  GluN2A2B(CTR) cultures
All cells voltage-clamped at -60mV and recorded between DIV 15-17. NMDA currents were evoked
by 150 µM NMDA + 100 µM glycine. Ifenprodil used at 3 µM and MK-801 at 10 µM.
(A) The whole-cell ifenprodil sensitivity of a WT DIV 15 neuron was determined in   0-Mg 2+ ACSF.
The neuron was then switch to an ACSF with 1 mM MgCl2 + 10µM MK-801 + 50 µM bicuculline
and allowed to fire phasically in the current-clamp configuration. After 5 minutes, the neuron was
switched back to the voltage-clamp configuration and the ifenprodil sensitivity at exNMDARs was
now determined.
(B) There  was  no  significant  difference  in  the  extrasynaptic   portion  of  WT  (23±3%)  and
GluN2A2B(CTR) (21±4%) neurons. n = 12 for both WT and GluN2A2B(CTR)
(C) Correlation of the whole-cell ifenprodil block and the ifenprodil block at exNMDARs only for
both WT and GluN2A2B(CTR)neurons. 
(D)The ifenprodil block at exNMDARs only was normalized to the ifenprodil block of the whole-cell
ifenprodil block. The average values for WT (1.22±0.05) and  GluN2A2B(CTR)(1.13±0.03) reveal that
there  was a  small  but  preferential  loss  of  GluN2B at  synNMDARs yet  there was  no significant




Student t-test(2tailed): P = 0.68
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5.2.3  GluN2A2B(CTR)  cultures  are  more  vulnerable  to  NMDAR-dependent
excitotoxicity
As the  GluN2A2B(CTR)  cultures  have  no  deficits  in  the  expression  of  endogenous
NMDARs, they can be utilized to test the hypothesis that these neurons   are more
vulnerable to excitotoxicity. By determining the dose-response relationship between
NMDA concentration and cell death, it was revealed that GluN2A2B(CTR) neurons had
enhanced  vulnerability  to  NMDA excitotoxicity  as  determined  by  a  significant
difference (P = 0.034) in the calculated  logEC50 values (GluN2A2B(CTR) = 12.0, WT =
17.7)(Figure 7A & 7B). 
As an aside, although 15 µM NMDA was quoted as non-toxic in chapter 3, this was
utilizing young rat cortical cultures rather than mature mouse cortical cultures used
here;  mouse  neurons  are  more  vulnerable  to  excitotoxicity  and  maturation  also
increases vulnerability to excitotoxicity. 
It can therefore be concluded, that in agreement with the over-expression studies,
replacing  the  GluN2A CTD  with  GluN2B  renders  neurons  more  vulnerable  to
NMDAR dependent excitotoxicity. Furthermore, in the same light as the reciprocal
GluN2B2A(CTR) study,  this  data  demonstrates  that  the  role  of  the  GluN2 CTD in
determining excitotoxicity is lost at high Ca2+  influx thus strengthening the concept
that the role of the GluN2 CTD in governing excitotoxicity is highly complex. 
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Figure 7:GluN2A2B(CTR) cultures are more vulnerable to NMDA-dependent
               excitotoxicity
(A) The  dose-response  relationship  between  NMDA concentration  and  cell  death  utilizing  an
increment of 10 µM NMDA was determined for DIV 17 sister WT and GluN2A(2BTC) cultures. The
1 hour NMDA exposure was terminated with 10 µM MK-801, the cells fixed 24 hours later and the
cell death subsequently determined. The averaged data was fitted using the dose-response equation
(see methods for elaboration). A significant difference (P = 0.034) in the calculated logEC50  values
(GluN2A2B(CTR) = 12.0 µM, WT = 17.7 µM). was observed using an extra sum of squares F-test. WT
R2 = 0.96, GluN2A2B(CTR)  R2  = 0.99. n = 3 independent cultures. Each n was determined by averaging
the cell death in 2 wells.
(B) Example DAPI images. Both WT and GluN2A2B(CTR) neurons have similar basal death at DIV 17
but GluN2A2B(CTR)  cultures have >90% neuronal death after a 1 hour exposure to 20 µM NMDA




5.2.4 The induction of several immediate early genes by synaptic activity is not
impaired in GluN2A2B(CTR) neurons
An increase in synaptic activity was achieved by inhibiting GABAA receptors in
DIV 17 cultures for 4 hours, utilizing 50 µM bicuculline, juxtaposed with a control
untreated group and a control group with 50 µM bicuculline pre-treated with 10 µM
MK-801 to block NMDARs. After the 4 hours stimulation, the RNA from both WT
and GluN2A2B(CTR) neurons was harvested in parallel and subsequently converted to
cDNA.  Subsequently, qRT-PCR was utilized to determine the mRNA expression of
a  neuroprotective  CREB  regulated  gene  (BDNF),  a  neuroprotective  CREB-
independent gene (NPAS4) and FOSB (as it  is  rapidly upregulated upon nuclear
Ca2+)  (Figures  8A/B/C).   It  is  evident  that  promoting  synaptic  activity  with
bicuculline increases the transcription of all three genes in an NMDAR-dependent
manner as the upregulation was readily blocked by MK-801. However, there was no
significant difference in  the expression of all  3 genes  after  4 hours of enhanced
synaptic activity between WT and GluN2A2B(CTR) cultures. 
It  can therefore  be concluded that  that  replacing  the  GluN2A CTD with that  of
GluN2B does not impede the transcription of the CREB target gene BDNF nor the
CREB-independent  gene  NPAS4  both  of  which  are  neuroprotective.  This  is
consistent with the evidence that it is the temporal and spatial profile of nuclear Ca2+
that largely determines the transcription of neuroprotective genes and is inconsistent
with reports that GluN2A-NMDARs exclusively mediate neuroprotection.  
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Figure 8: The induction of several immediate early genes by synaptic activity is
not impaired in GluN2A2B(CTR) neurons
 
(A-C) Using the qRT-PCR method, the mRNA expression of FOSB (A), NPAS4 (B) and BDNF (C)
were  measured  in  the  following  conditions  for  4  hours  at  DIV  17:  untreated  control;  50  µM
bicuculline; 50 µM bicuculline + 10 µM MK-801. 50 µM bicuculline increased the transcription of
all 3 genes which could be reduced by 10 µM MK-801 confirming the upregulation was NMDAR-
dependent. There was no significant difference in the mRNA expression of all three genes after being
treated for 4 hours with bicuculline.   p > 0.05, student unpaired t-test (2-tailed). n = 4 independent









It can therefore be concluded that when both GluN2A and GluN2B are subjected to
regulation by CK2 and other specific post-translational modifications at the GluN2B
CTD, the developmental upregulation of GluN2A still occurs indicating that CTD-
subtype  specific  interactions  are  not  required  contrary  to  current  models.
Consequently, this permits the downstream signalling in GluN2A2B(CTR) cultures to be
studied as discussed below. 
5.3.2  The  role  of  the  GluN2  CTD  in  the  developmental  upregulation  of
GluN2A-NMDARs
As previously discussed,  it has been proposed that Ca2+ -activated CaMKII  binds to
CK2, independent of its kinase activity,  where it promotes CK2 phosphorylation of
the GluN2B C-terminus at S1480. This has the functional consequence of disrupting
the  interaction  of  of  GluN2B  with  MAGUK  proteins  ultimately  leading  to
endocytosis  at  extrasynaptic  sites  via  clathrin-AP-2-mediated endocytosis  (Sanz-
Clemente et al. 2010; Chen et al. 2012; Sanz-Clemente et al. 2013).The capacity of
S1480  phosphorylation  to  drive  endocytosis  is  almost  maximal.  This  is  most
elegantly and beautifully  demonstrated  by the  transfection  of  a  phosphomimetic
S1480E  GluN2B  into  GluN2A-/-/GluN2B-/- hippocampal  slice  cultures;  whereas
transfection of WT GluN2B permitted ~90%  recovery of EPSC, transfection of
S1480E  GluN2B  strikingly  provided  no  recovery  of  the  EPSC.  Even  more
fascinatingly,  the effect of S1480E could be abolished by mutating D1391K and
D1392K which disrupts the N-terminal of SAP-102 promoting endocytosis. 
However,  whereas the use of over-expression and phosphomimetic mutations are
excellent in unequivocally demonstrating the existence of a signalling pathway, it
does not address the role of the pathway under physiological conditions. This was
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firstly addressed by the utilization of the CK2 inhibitor TBB in cortical cultures. It
was  observed  that  overnight  incubation  of  DIV  10  cortical  cultures  with  TBB
decreased the surface:total ratio of GluN2A protein expression whilst reciprocally
increasing that of GluN2B  (Sanz-Clemente et al. 2010). However in our hands, DIV
10 neurons predominately express diheteromeric GluN2B NMDARs. Therefore, this
is a developmental time point in which GluN2A is minimally expressed; the effect of
CK2 inhibition may be lost when other developmental programmes, such as changes
in the transcription of Grin2a and Grin2b, occur naturally at a later developmental
time point as used in this study. 
Synaptic plasticity requires more rapid changes in synaptic composition thus making
post-translational  modification  of  the  GluN2B  CTD  ideal.  The  LTP  induction
protocol which induces a rapid upregulation of GluN2A at the synapse is highly
excitatory (voltage-clamping CA1 neurons at 0mV whilst stimulating the Schaffer
collateral  axons at  1Hz for 120 seconds) and therefore the rapid upregulation of
GluN2A may function to dampen the insertion of AMPA receptors at the synapse
(Gray et al. 2011). It should also be stressed that whilst mGluR5-/-  mice have a small
but significant deficit in the expression of GluN2A containing NMDARs receptors
in CA1 hippocampal neurons, blocking mGluR5 with MTEP in young hippocampal
neurons completely abolishes the rapid upregulation of GluN2A induced by the LTP
protocol (Matta et al. 2011). Therefore, the LTP protocol may be highly sensitive to
post-synaptic Ca2+ changes to a degree which is not physiologically relevant; indeed,
there is no compensatory mechanism in this system as blocking either NMDARs
alone or mGluR5 alone completely abolishes the upregulation of GluN2A. As an
aside, the LTP protocol described above was utilized in rat hippocampal slices and if
used in mouse hippocampal slices,  it  fails  to induce an upregulation of GluN2A
(Matta, et al.  2011); the reason for this is unclear. Nevertheless,  it  is clear CK2
phosphorylation of the GluN2B CTD is critical in this developmental upregulation
of  GluN2A  upon  the  induction  of  the  LTP  protocol  as  demonstrated  by  the
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antagonism by the CK2 inhibitor TBB (Sanz-Clemente et al. 2010). 
On the other hand it is evident from chapter 4, that by increasing Grin2a mRNA by
transfection,  a  replacement  of  GluN2B  with  that  of  GluN2A at  the  neuronal
membrane can occur within 48 hours. It is therefore reasonable to assume that a
developmental change in GluN2B endocytosis is not an absolute pre-requisite for
GluN2A expression at the neuronal membrane. Determined by single-cell RT-PCR,
there  is  a  strong correlation  between  Grin2a expression  and  a  fall  in  ifenprodil
sensitivity in cortical cultures  (Hoffmann et al.  2002). Furthermore, the temporal
pattern  of  Grin2a transcription  (Watanabe et  al.  1992;  Monyer  et  al.  1994)  and
GluN2A  expression  (Sheng  et  al.  1994;  Portera-Cailliau  et  al.  1996)  in  vivo
corresponds excellently with electrophysiological data suggesting incorporation of
GluN2A containing NMDARs at the synapse (Kirson & Yaari  1996).  Epigenetic
silencing  of  Grin2b has  been  proposed  to  be  essential  for  the  development
upregulation of GluN2A (Rodenas-Ruano et al.  2012). Altogether, this suggests a
prominent role for the protein expression of GluN2A and GluN2B in determining
the  upregulation  of  GluN2A containing  NMDARs  rather  than  post-translational
modification. 
The major advantage of replacing the GluN2A CTD with that of GluN2B in this
study  is  that  it  permits  the  evaluation  of  the  CTD  without  the  need  for  over-
expressing  proteins  of  interest  nor  utilizing  pharmacology  to  acutely  perturb
homoeostasis. Here, when both GluN2A and GluN2B NMDARs are subjected to the
same  regulation  via  the  CTD  in  GluN2A2B(CTR)  neurons,  the  developmental
upregulation of GluN2A and synaptic targetting of NMDARs is the same as WT
neurons.  This  suggests  that  selective  CK2-dependent  regulation  of  the  GluN2B
CTD is not required for the developmental upregulation of GluN2A at the neuronal
membrane in cortical cultures. 
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I  propose  the conflicting results  can  be explained by the initial  observation  that
GluN2A upregulation can occur in both an artificially created culture system in a
time period of days, but also in hippocampal slices in a matter of minutes induced by
an LTP protocol. It has largely been assumed that the two mechanisms of GluN2A
upregulation  are  correlated  but  the  evidence  for  this  is  lacking.  The  slow
developmental upregulation of GluN2A is likely mediated through transcriptional
and translational mechanisms whereas the rapid upregulation of GluN2A induced by
LTP protocols  requires  the  faster  mechanism  of  post-translational  modifications
including that of the GluN2B CTD. 
It is also interesting to note that dark rearing rats from birth can result in an increase
in the phosphorylation of ser1303 at the GluN2B CTD, juxtaposed with a decrease
in  the  protein  expression  of  GluN2A:GluN2B,  which  correlates  with  a  delayed
upregulation of GluN2A in the visual cortex and retina; even more remarkable, only
6  hours  of  light  can  reverse  both  the  delayed  expression  of  GluN2A and  the
increased phosphorylation of ser1303 (Giannakopoulos et al. 2010). Phosphorylation
of  ser1303  would  prevent  CaMKII  binding  and  therefore  block  CK2  regulated
endocytosis of GluN2B NMDARs making this  an attractive mechanism to partly
explain this form of metaplasticity. Repeating the experiments in GluN2AB(CTR) mice
would permit the testing of this hypothesis. 
For completeness, it has been reported that blockade of NMDARs and AMPARs has
been  reported  to  increase  GluN2A  expression  within  hours  with  no  effect  on
GluN2B expression  in  culture  (von  Engelhardt  et  al.  2009).  As  TTX could  not
reproduce  this  effect,  it  must  be  presumed  this  effect  is  due  to  blocking  action
potential independent miniature release of glutamate at the synapse (“minis”) which
can  tonically  suppress  local  dendritic  protein  synthesis  (Sutton  et  al.  2006).
Nevertheless, this phenomenon has yet to be explored in any great detail.
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5.3.3 The role of the GluN2 CTD in excitotoxicity
The data presented here demonstrate GluN2A2B(CTR)  cultures are more vulnerable to
excitotoxicity  in  a  concentration-dependent  manner.  This  result  is  in  excellent
accordance with over-expression of GluN2A2B(CTR) in young DIV 9-10 neurons being
more vulnerable to excitotoxicity but also the  in vitro and  in vivo data from the
reciprocal GluN2B2A(CTR) mouse line having reduced vulnreability to excitotoxicity
(Martel et al. 2012). This work could easily be expanded by investigating signalling
cascades  involved  in  the  GluN2B CTD preferentially  coupling  to  excitotoxicity.
Initially, the most obvious candidate would be the previous identified PSD-95-nNOS
pathway preferentially coupling to CREB shut-off (Soriano et al. 2008; Martel et al.
2012)  but other mechanisms, such as the phosphorylation of the GluN2B CTD by
DAPK1 (Tu et al. 2010) could also be investigated. 
An interesting and open question is  to what  extent  does one GluN2B CTD in a
triheteromeric NMDAR saturate preferential excitotoxic signalling? Unfortunately,
this  cannot be addressed with the current approach. Nevertheless,    coupling the
GluN2A2B(CTR) and GluN2B2A(CTR) constructs with the recently developed approach to
isolate triheteromeric NMDARs (Hansen et al. 2014) would be a promising strategy
to address this question. 
The data presented here strengthens the concept that the GluN2B CTD is a valuable
target  to  disrupt  in  order  to  uncouple  the  NMDAR from excitotoxicity.  From a
clinical perspective, it  is promising that disrupting the interaction of the GluN2B
CTD and PSD-95, utilizing NA-1/Tat-NR2B9c, has the beneficial effect of not only
reducing lesion size but also improving general outcome of non human primates
post stroke (Cook et  al.  2012). Furthermore, in a phase II clinical trial assessing
whether NA-1/Tat-NR2B9c would be beneficial in reducing the pathophysiological
outcome post intracranial aneurysm, NA-1/Tat-NR2B9c was found to reduce lesion
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size 12-95 hours after infusion (Hill et al. 2012). Further research will be needed to
determine  the  therapeutic  potential  of  NA-1/Tat-NR2B9c  in  stroke  and  other
neurodegenerative diseases. 
5.3.4 The role of the GluN2 CTD in the transcription of neuroprotective genes
Nuclear  Ca2+ concentrations  is  a  major  determinant  in  the  transcription  of
neuroprotective genes  (Hardingham et al.  1997; Zhang et al.  2009; Bading 2013)
and  neurons  that  predominantly  express  diheteromeric  GluN2B  NMDARs  are
capable of upregulating neuroprotective genes upon synaptic activity. Therefore, the
proposition that GluN2A NMDARs exclusively mediate neuroprotective signalling
(Liu  et  al.  2007)  is  surprising.  As selective  Ca2+ influx  through L-type  voltage-
operated calcium channels (VOCCs) can also result in the activation of CREB and
promote the transcription of neuroprotective genes, it is unlikely subtle differences
in  the  biophysical  properties  of  GluN2A and  GluN2B  could  impart  selective
neuroprotective signalling to GluN2A.  As an aside, it now appears the major source
of somatic/nuclear Ca2+ during synaptic activity is through VOCCs with Ca2+ influx
through synNMDARs functioning to  amplify this  signal  (Bengtson  et  al.  2013).
Nevertheless, it is logical that any potential selective neuroprotective signalling is
through the GluN2A CTD rather than biophysical properties. 
However, the mRNA expression of a neuroprotective CREB regulated gene (BDNF)
and a neuroprotective CREB-independent gene (NPAS4) were equally upregulated
in WT and GluN2A2B(CTR)cultures upon synaptic activity. This suggests the GluN2
CTD  subtype  is  not  relevant  in  the  transcriptional  upregulation  of  these  genes
despite reports that GluN2A and gluN2B differentially regulate BDNF (M. Chen et
al. 2008). This discrepancy and that of Liu et. al. are likely explained by the use of a
concentration of NVP (400 nM) which blocks both GluN2A and GluN2B NMDARs,
with the intention of selectively blocking GluN2A.
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Nevertheless, it is feasible that a small subset of genes are differentially regulated by
the  GluN2A and  GluN2B  CTD.  To  address  this,  the  above  experiments  were
designed  so  that  there  is  sufficient  RNA  from  the  control  and  bicuculline
experiments to run an RNA-seq experiment utilizing current Illumina sequencing
technology if required in the near future. 
5.3.5 Limitations and advantages of experimental approach
To summarize previous points, replacing the Glun2A CTD with that of the GluN2B
CTD  circumnavigates  the  need  to  overexpress  proteins  of  interests  which  can
produce off-target effects. This approach also allows the developmental upregulation
of GluN2A to be monitored without pharmacological perturbation of homoeostatic
conditions. Also, as previously discussed, the poor selectivity of NVP-AAM077 has
led to conflicting evidence regarding the role of GluN2A in NMDAR signalling and
the  dependency  of  TCN  201  and  TCN  213  on  concentration  of  the  co-agonsit
glycine/D-serine is a major hindrance on their use for the same purpose (see chapter
4);  therefore,  genetic  manipulation  of  GluN2  subunits  are  still  essential  for
understanding NMDAR dependent signalling. 
On the other hand, it could be argued that replacing the entire GluN2A CTD with
GluN2B can lead to off-target effects itself. Therefore, this study would benefit from
a greater understanding of the physiological state of the GluN2B CTD incorporated
into the GluN2A subunit; this include post-translational modifications of the CTD
and identifying its key binding partners. 
Additionally, another approach to investigate the role of CAMKII in the regulation
of GluN2B-NMDARs surface expression at the membrane is to utilize a knock-in
mouse where the CAMKII binding site on the GluN2B CTD is mutated; this avoids
the off-target effects of either overexpressing mutated GluN2B subunits  (as used
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The introduction to  this  thesis  clearly identifies that  the NMDAR can couple to
multiple physiological and pathophysiological signalling cascades. It is evident that
this is possible because the biological outcome of NMDAR activation is determined
by  a  complicated  interrelationship  between  the  concentration  of  Ca2+ influx,
NMDAR  location  as  well  as  the  subtype  of  the  GluN2  subunit.  Despite  the
recognition that NMDAR mediated physiology is multifaceted, tools used to study
subunit  and  location  dependent  signalling  are  poorly  characterized  and  in  other
cases,  non-existent.  The  research  reported  herein  has  addressed  this  issue  by
establishing the following three key findings:
• Contrary to the current dogma, MK-801  blockade is unstable during tonic
agonist exposure in the presence of physiologically relevant concentrations
of  Mg2+.  This  confines  a  temporal  limit  in  which  selective  activation  of
exNMDARs can occur. 
• Novel  GluN2A  antagonists,  TCN  201  and  TCN  213,  can  detect  a
developmental upregulation of GluN2A during cortical culture maturation.
• Genetically replacing the GluN2A CTD with GluN2B does not impede the
developmental  upregulation  of  GluN2A  nor  the  induction  of  several
immediate genes by synaptic activity. It does, however, render neurons more
vulnerable to NMDAR-dependent excitotoxicity. 
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It is hoped the identification of these findings will impact future studies aimed at
elucidating the complex signalling of the NMDAR. Firstly, the data in  chapter 3
demonstrate  it  is  relatively  difficult  to  selectively  activate  exNMDARs  and
synNMDARs  under  the  same  temporal  profile  utilizing  MK-801;  current  data
acquired using this experimental paradigm must be re-assessed in this new light. On
a  longer  time  scale,   as  there  is  a  great  deal  of  interest  in  selective  signalling
downstream of  synNMDARs and  exNMDARs  (Giles  E.  Hardingham & Bading
2010) another  experimental  strategy  is  clearly  required  to  dissect  out  cellular
signalling by spatially distinct populations of NMDARs. Consequently, the use of
glutamate or MK-801 uncaging is  arguably the most promising avenue currently
available.  Another  potential  approach  involves  involves  using  enzymes  which
degrade the NMDAR co-agonists glycine and D-serine; it has been demonstrated
that  under  physiological  conditions,  degrading  D-serine  effects  the  activation  of
synNMDARs whereas degrading glycine effects the activation of exNMDARs in
hippocampal slices (Papouin et al. 2012). This of course would have to be verified to
function in every new system utilized and also shown to function under any change
to the system such as inducing an excitotoxic insult. 
Secondly, the data in  chapter 4 demonstrate novel GluN2A antagonists, TCN 201
and TCN 213, can inhibit endogenously expressed GluN2A containing NMDARs.
This  is  noteworthy  as  both  compounds  are  the  first  class  of  selective  GluN2A
antagonists.  These  compounds  were  utilized  to  demonstrate  a  developmental
upregulation of GluN2A, which concurrently dilutes the contribution of GluN2B-
NMDARs. This observation is in agreement with a noted increase of  grin2a and
GluN2A expression, juxtaposed with a decrease in grin2b and GluN2B expression,
during  forebrain  development.   Moreover,  this  study also  advocates  that  further
determination of TCN 201 potency at triheteromeric GluN2A-GluN2B NMDARs
would be invaluable in the interpretation of not only the data presented herein but
also future studies. However, the potency of these compounds is determined by the
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concentration of glycine/D-serine acting as a co-agonist at the NMDAR. Therefore,
it absolutely paramount that any future studies utilizing these compounds ensure that
the glycine/D-serine concentrations at synaptic and extrasynaptic sites is determined
in order that an expected antagonism is gauged. To date, in vitro studies (Costa et al.
2012; Shin et al. 2012; Hargus & Thayer 2013)  utilizing TCN 201 have failed to
demonstrate direct antagonism of TCN 201 in the system used yet correlate a lack of
TCN 201  modifying  a  biological  effect  with  GluN2A containing  NMDARs not
being involved in  the signalling cascade observed.  Consequently,  it  is  extremely
difficult to interpret the data from these studies; it is hoped this is remedied in future
studies in order that complex subunit-dependent signalling by NMDARs signalling
is elucidated correctly. 
Lastly, data in chapter 5 reveal that selective post-translational modification of the
GluN2B CTD is not an absolute pre-requisite for the developmental upregulation of
GluN2A to  occur  in  a  cortical  culture  system.  This  was  was  concluded  by the
replacement  of  the  GluN2A CTD with  that  of  GluN2B in  order  that  all  GluN2
subunits  were  subjected  to  the  same  post-translational  modifications;  it  was
observed developmental upregulation of GluN2A was not impeded. However, this
study does not exclude the possibility that the post-translational modification of the
GluN2B CTD may be critical for other forms of GluN2A upregulation including that
induced  by  synaptic  plasticity.  Furthermore,  it  was  revealed  that  replacing  the
GluN2A  CTD  with  GluN2B  rendered  neurons  more  vulnerable  to  NMDAR-
dependent excitotoxicity thus strengthening the concept that the GluN2B CTD is a
valuable target  to  disrupt in  order  to  uncouple the NMDAR from excitotoxicity.
Future research into the usefulness of disrupting the interaction of the GluN2B CTD
and  PSD-95,  utilizing  NA-1/Tat-NR2B9c,    may yield  an  important  therapeutic
strategy  in  treating  stroke  and  neurodegenerative  diseases.   Moreover,  the
observation that the induction of neuroprotective immediate early genes by synaptic
activity were not impaired in GluN2A2B(CTR) neurons supports  the hypothesis  that
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nuclear Ca2+  may be the main determinant in the transcription of neuroprotective
genes. This further supports the use of NA-1/Tat-NR2B9c as a neuroprotective agent
as disrupting the GluN2B CTD may minimally effect neuronal survival signalling as
previously shown by Martel et al., 2009. 
An overarching theme maintained throughout this thesis is that carefully designed
and complex tools  are needed to study the NMDAR. The need for such elegant
experimental  approaches  arises  from  the  composite  structure  of  the  NMDAR
juxtaposed with the intricate signalling cascades the receptor can couple to. Future
research will undoubtedly develop new and exciting avenues to explore the role of
this fascinating receptor in mediating essential physiological and pathophysiological
functions in the nervous system. 
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